Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like all*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000077	AbbVie	03/31/2022	00074081702	(adalimumab) HUMIRA 10MG/0.1ML PFS 2-PACK	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074006702	(adalimumab) HUMIRA 1X80MG,0.8ML, 1X40MG,0.4ML PFS2PKPED CROHN'S STARTER PACK	01/14/2022	662.47	9614.78	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074061602	(adalimumab) HUMIRA 20MG/0.2ML PFS 2-PACK	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074433902	(adalimumab) HUMIRA 40MG/0.8 ML (2 PENS)	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074379902	(adalimumab) HUMIRA 40MG/0.8ML (2 SYRINGES)	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074254003	(adalimumab) HUMIRA 80MG, 0.8ML PFS 3-PACKPED CROHN'S STARTER PACK	01/14/2022	1324.95	19229.57	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074012403	(adalimumab) HUMIRA CROHN'S 80MG/0.8ML, 3 PENS STARTER PACK	01/14/2022	1324.95	19229.57	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074055402	(adalimumab) HUMIRA PEN, 40MG/0.4ML, 2 PENS	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074024302	(adalimumab) HUMIRA PFS, 40MG/0.4ML, 2 SYRINGES	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074153903	(adalimumab) HUMIRA PSORIASIS; 1X80MG, 2X40MG (3PENS) STARTER PACK	01/14/2022	883.29	12819.69	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074433906	(adalimumab) HUMIRA, CROHN'S, 40MG/0.8 ML (6 PENS) STARTER PACK	01/14/2022	1324.95	19229.57	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074433907	(adalimumab) HUMIRA, PSORIASIS, 40MG/0.8ML (4 PENS) STARTER PACK	01/14/2022	883.29	12819.69	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074003828	(elagolix sodium) ORILISSA 150MG TABS, 4X7 PACK	01/14/2022	72.12	1046.66	09/01/2036	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074003956	(elagolix sodium) ORILISSA 200MG TABS, 4X14 PACK	01/14/2022	72.12	1046.66	09/10/2024	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074244003	(leuprolide acetate) LUPRON DEPOT PED, 15 MG PDS KIT	01/14/2022	174.82	3742.62	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074377903	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 11.25MG	01/14/2022	476.18	10194.21	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074969403	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 30MG	01/14/2022	524.47	11227.90	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074210803	(leuprolide acetate) LUPRON DEPOT PED, 7.5 MG PDS KIT	01/14/2022	87.43	1871.71	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074366303	(leuprolide acetate) LUPRON DEPOT, GYN,3 MONTH 11.25 MG PDS KIT	01/14/2022	218.03	4667.64	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074364103	(leuprolide acetate) LUPRON DEPOT, GYN,3.75 MG PDS KIT	01/14/2022	72.68	1555.87	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074334603	(leuprolide acetate) LUPRON DEPOT, URO,3 MONTH 22.5 MG PDS KIT	01/14/2022	259.81	5562.15	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074368303	(leuprolide acetate) LUPRON DEPOT, URO,4 MONTH 30 MG PDS KIT	01/14/2022	346.42	7416.22	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074364203	(leuprolide acetate) LUPRON DEPOT, URO,7.5 MG PDS KIT	01/14/2022	86.61	1854.06	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074228203	(leuprolide acetate) LUPRON DEPOT-PED 11.25 MG PDS KIT	01/14/2022	158.73	3398.06	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074347303	(leuprolide acetate) LUPRON, URO,45MG 6MTH	01/14/2022	519.64	11124.49	02/05/2031	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032121201	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 100CAP	01/14/2022	21.99	376.72	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032121207	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 250CAP	01/14/2022	54.98	941.79	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032122401	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 100CAP	01/14/2022	43.60	746.73	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032122407	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 250CAP	01/14/2022	107.23	1836.75	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032120370	(lipase/protease/amylase) CREON 3000USP DELAYED-RELEASE 70CAP	01/14/2022	6.50	111.43	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032301613	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 100CAP	01/14/2022	66.20	1133.82	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032301628	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 250CAP	01/14/2022	165.46	2834.20	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032120601	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 100CAP	01/14/2022	11.00	188.47	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032120607	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 250CAP	01/14/2022	27.51	471.22	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074204202	(risankizumab-rzaa) SKYRIZI 75MG/0.83ML PFS x2 US/PR	01/14/2022	1259.02	18272.79	02/04/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057634	(venetoclax) VENCLEXTA 100MG BOTTLE 180 TABLETS*	07/05/2022	505.84	20739.36	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057622	(venetoclax) VENCLEXTA 100MG BOTTLE, 120 TABLETS*	07/05/2022	337.23	13826.24	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057611	(venetoclax) VENCLEXTA 100MG UNIT DOSE, 1 TABLET*	07/05/2022	2.81	115.21	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056111	(venetoclax) VENCLEXTA 10MG UNIT DOSE, 2 TABLETS*	07/05/2022	0.56	23.04	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056114	(venetoclax) VENCLEXTA 10MG WALLET, 2 TABLETS X 7*	07/05/2022	3.93	161.30	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056611	(venetoclax) VENCLEXTA 50MG UNIT DOSE, 1 TABLET*	07/05/2022	1.41	57.61	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056607	(venetoclax) VENCLEXTA 50MG WALLET, 1 TABLET X 7*	07/05/2022	9.84	403.27	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057928	(venetoclax) VENCLEXTA START PACK, 4X7 DAY WALLET*	07/05/2022	72.78	2984.16	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	03/31/2022	63090010030	Nuplazid Oral Tablet 10mg - 30 each	02/05/2022	193.00	4173.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	09/30/2022	63090010030	Nuplazid Oral Tablet 10mg, 30 tablets	08/23/2022	392.00	4565.00	08/27/2038	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	03/31/2022	63090034030	Nuplazid Oral Tablet 34mg - 30 each	02/05/2022	193.00	4173.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	09/30/2022	63090034030	Nuplazid Oral Tablet 34mg, 30 tablets	08/23/2022	392.00	4565.00	08/27/2038	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000278	Acella Pharamceuticals, LLC	03/31/2022	42192071401	Ciclopirox Treatment External Kit 8%, solution, 34.6 ML, unit of size 1 box	01/17/2022	46.91	362.91	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug not acquired within the past five years
Rx0000278	Acella Pharamceuticals, LLC	03/31/2022	42192060840	Gabapentin 300mg/6ml US 40	01/17/2022	12.38	137.38	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	columns were left blank because this product was not acquired from another manufacturer in the last five years.
Rx0000454	AcelRx Pharmaceuticals, Inc.	12/31/2022	61621043001	Dsuvia Sublingual Tablet Sublingual 30 MCG	10/01/2022	9.61	73.73	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000454	AcelRx Pharmaceuticals, Inc.	12/31/2022	61621043011	Dsuvia Sublingual Tablet Sublingual 30 MCG, 10 Each, Unit-Dose, Box	10/01/2022	96.17	737.32	07/29/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2022	48818000101	Folotyn (Pralatrexate) IV Inj 20 MG/ML, 1 ML, Unit-Dose, Vial	10/04/2022	257.20	6687.21	05/31/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2022	48818000102	Folotyn (Pralatrexate) IV Inj 40 MG/2ML, 2 ML, Unit-Dose, Vial	10/04/2022	514.40	13374.42	05/31/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061006	UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061206	UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061406	UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061606	UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060214	UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet	09/15/2022	1308.11	31729.30	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060206	UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet	09/15/2022	560.62	13598.27	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215062820	UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet	09/15/2022	1308.10	31729.05	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060406	UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060606	UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060806	UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000328	Adamas Pharmaceuticals, Inc.	09/30/2022	70482017060	Gocovri Oral Capsule Extended Release 24 Hour 137 MG, 60 Each, Bottle	07/01/2022	142.54	2993.29	08/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	09/30/2022	70482008560	Gocovri Oral Capsule Extended Release 24 Hour 68.5 MG, 60 Each, Bottle	07/01/2022	142.54	2993.29	08/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431011001	JUXTAPID 10 MG CAPS, bottle of 28 capsules	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431012001	JUXTAPID 20 MG CAPS, bottle of 28 capsules	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431013001	JUXTAPID 30 MG CAPS, bottle of 28 capsules	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431010501	JUXTAPID 5 MG CAPS - bottle of 28	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431021001	MYALEPT 11.3MG VIAL	01/01/2022	238.37	5535.42	12/31/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000477	Agile Therapeutics	09/30/2022	71671010003	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Box Qty 3	07/15/2022	16.43	191.20	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000477	Agile Therapeutics	09/30/2022	71671010011	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Package	07/15/2022	5.47	63.73	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi company	09/30/2022	71369002010	DOPTELET, 1 BLISTER PACK in 1 CARTON > 10 TABLET, EQ 20MG BASE	07/01/2022	244.20	3733.40	05/05/2025	Single Source Drug	None	1	AkaRx (and its affiliated companies) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to: a) the clinical value of the medicine; b) the economic value of the medicine; c) market dynamics and competitor pricing; d) discounts provided to customers in the public and private sectors; and e) patient support provided by AkaRx to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi company	09/30/2022	71369002015	DOPTELET, 1 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE	07/01/2022	366.30	5600.10	05/05/2025	Single Source Drug	None	1	AkaRx (and its affiliated companies) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to: a) the clinical value of the medicine; b) the economic value of the medicine; c) market dynamics and competitor pricing; d) discounts provided to customers in the public and private sectors; and e) patient support provided by AkaRx to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi company	09/30/2022	71369002030	DOPTELET, 2 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE	07/01/2022	732.60	11200.20	05/05/2025	Single Source Drug	None	1	AkaRx (and its affiliated companies) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to: a) the clinical value of the medicine; b) the economic value of the medicine; c) market dynamics and competitor pricing; d) discounts provided to customers in the public and private sectors; and e) patient support provided by AkaRx to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000417	Akebia Therapeutics, Inc.	03/31/2022	59922063101	AURYXIA (ferric citrate) 210 mg Tablets: Bottle of 200	01/19/2022	84.00	1364.00	07/21/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000417	Akebia Therapeutics, Inc.	06/30/2022	59922063101	AURYXIA (ferric citrate) 210 mg Tablets: Bottle of 200	04/15/2022	30.00	1394.00	07/21/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000085	Akorn Inc	12/31/2022	17478025310	AK-FLUOR 10% SOLN; VIAL; 5mL; 12 VIALS	10/24/2022	288.00	864.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000085	Akorn Inc	12/31/2022	17478025020	AK-FLUOR 25% SOLN; VIAL; 2mL; 12 VIALS	10/24/2022	288.00	864.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	03/31/2022	52427065830	Loreev XR 1 mg extended-release capsules, 30 count	03/14/2022	140.00	425.00	01/08/2034	Single Source Drug	893	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	03/31/2022	52427066330	Loreev XR 2 mg extended-release capsules, 30 coun	03/14/2022	140.00	425.00	01/08/2034	Single Source Drug	1209	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	03/31/2022	52427066730	Loreev XR 3 mg extended-release capsules, 30 coun	03/14/2022	140.00	425.00	01/08/2034	Single Source Drug	730	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000459	AltaThera Pharmaceuticals LLC	03/31/2022	69724011210	Sotalol hydrochloride 15mg/mL 10mL Vial	01/01/2022	246.00	2734.00	04/05/2039	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=667	None
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012630	10mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012730	20mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012830	40mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012530	5mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000230	Roszet 10mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000330	Roszet 20mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000430	Roszet 40mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000130	Roszet 5mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000436	Amdipharm Limited	06/30/2022	59212042204	Donnatal Oral Elixir 16.2 MG/5ML	04/01/2022	38.00	450.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212042304	Donnatal Oral Elixir 16.2 MG/5ML 16.2-0.1037-0.0194-0.0065 MG/5ML, 120 ML, Bottle	04/01/2022	38.00	450.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212042316	Donnatal PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle	04/01/2022	146.00	1795.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024255	Lanoxin Oral Tablet 125 MCG	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024256	Lanoxin Oral Tablet 125 MCG, 100 Each, Unit-Dose, Box	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024955	Lanoxin Oral Tablet 250 MCG	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024055	Lanoxin Oral Tablet 62.5 MCG	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212042216	PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle	04/01/2022	146.00	1795.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	09/30/2022	59212056210	Plaquenil Oral Tablet 200 MG	07/01/2022	106.48	1210.00	03/30/1968	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212068010	Zonegran Oral Capsule 100 MG	04/01/2022	174.00	2020.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212068110	Zonegran Oral Capsule 25 MG	04/01/2022	133.00	1560.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000231	American Health Packaging	03/31/2022	68001031356	AZACITIDINE POWDER 100MG SINGLE DOSE VIAL	01/01/2022	27.39	311.28	None	Non-innovator Multiple Source Drug	26154	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=589, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=601	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001050454	AZACITIDINE POWDER INJ 100MG SINGLE DOSE VIAL	01/01/2022	27.39	311.28	None	Non-innovator Multiple Source Drug	5184	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=590, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=602	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	68084069701	BUPROPION HCL ER (SR) TABLET 100MG 100UD	04/01/2022	8.82	80.00	None	Non-innovator Multiple Source Drug	2184	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	60687042321	CLOBAZAM TABS 10MG 30UD C4	02/01/2022	13.00	78.00	None	Non-innovator Multiple Source Drug	3174	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=600, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=612	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001044327	CYCLOPHOSPHAMIDE 1GM x 50ML STERILE POWDER SINGLE DOSE VIAL	01/01/2022	73.25	732.50	None	Non-innovator Multiple Source Drug	2533	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=591, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=603	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001044226	CYCLOPHOSPHAMIDE 500MG x 25ML STERILE POWDER, SINGLE DOSE VIAL	01/01/2022	36.62	366.25	None	Non-innovator Multiple Source Drug	2543	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=593, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=605	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001044432	CYCLOPHOSPHAMIDE VL 2GM x 100ML STERILE POWDER, SINGLE DOSE VIAL	01/01/2022	146.50	1465.00	None	Non-innovator Multiple Source Drug	481	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=592, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=604	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	62584015901	DEMECLOCYCLINE HCL TABLET 150MG 100UD	04/01/2022	63.05	693.51	None	Non-innovator Multiple Source Drug	297	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2022	60687019501	DILTIAZEM HCI CAPSULE ER 24H 120MG 100UD	07/05/2022	35.80	80.55	None	Non-innovator Multiple Source Drug	5172	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	60687019501	DILTIAZEM HCL ER CAP	02/01/2022	11.75	44.75	None	Non-innovator Multiple Source Drug	5784	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=596, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=608	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001034836	GEMCITABINE INJ 1GM/10ML 100MG/ML MULTIPLE DOSE VIALS-dose vials	01/01/2022	18.54	55.44	None	Non-innovator Multiple Source Drug	18360	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=594, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=606	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001035937	GEMCITABINE INJ 2GM/20ML 100MG/ML MULTIPLE DOSE VIALS	01/01/2022	23.53	105.60	None	Non-innovator Multiple Source Drug	3928	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=595, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=607	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2022	60687022901	LOPERAMIDE HCL CAPSULE 2MG 100UD	07/05/2022	17.94	85.00	None	Non-innovator Multiple Source Drug	9240	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2022	60687040825	MESALAMINE DR TABLET 800MG 30UD	08/30/2022	95.90	410.00	None	Non-innovator Multiple Source Drug	672	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	62584081201	OXAZEPAM CAP 10mg 10x10	02/01/2022	39.75	238.50	None	Non-innovator Multiple Source Drug	300	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=597, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=609	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	62584081301	OXAZEPAM CAP 15mg 10x10	02/01/2022	43.75	262.48	None	Non-innovator Multiple Source Drug	542	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=598, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=610	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	62584081401	OXAZEPAM CAP 30mg 10x10	02/01/2022	48.56	291.36	None	Non-innovator Multiple Source Drug	130	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=599, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=611	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	68084084401	VENLAFAXINE TABLET 37.5MG 100UD	04/01/2022	18.24	85.78	None	Non-innovator Multiple Source Drug	2412	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	68084085601	VENLAFAXINE TABLET 75MG 100UD	04/01/2022	19.90	93.59	None	Non-innovator Multiple Source Drug	1848	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	60687049301	VERAPAMIL HCL ER TABLET 120MG 100UD	04/01/2022	29.94	140.82	None	Non-innovator Multiple Source Drug	480	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	60687050401	VERAPAMIL HCL ER TABLET 180MG 100UD	04/01/2022	32.06	150.81	None	Non-innovator Multiple Source Drug	616	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128	American Regent	03/31/2022	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	02/01/2022	9.20	240.10	None	Non-innovator Multiple Source Drug	9037	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	Caffeine & Sodium Benzoate is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	06/30/2022	17.40	257.50	None	Non-innovator Multiple Source Drug	9037	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Caffeine & Sodium Benzoate is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517970225	DROPERIDOL, 2.5MG/ML, 2ML SDV, PKG. OF 25	06/27/2022	10.25	215.25	None	Non-innovator Multiple Source Drug	25765	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Droperidol is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517042001	ESTRADIOL VALERATE INJ., USP 100MG/5ML, (20 MG/ML)	06/27/2022	5.35	139.07	None	Non-innovator Multiple Source Drug	125119	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	06/30/2022	00517044001	ESTRADIOL VALERATE INJECTION, USP 200 MG /5 ML, (40 MG/ML)	06/27/2022	8.87	230.72	None	Non-innovator Multiple Source Drug	44451	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	06/30/2022	00517420125	HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25	06/27/2022	27.75	580.50	None	Non-innovator Multiple Source Drug	6056	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517560125	HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25	06/27/2022	30.50	640.25	None	Non-innovator Multiple Source Drug	8953	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	12/31/2022	00517065001	INJECTAFER, 750MG IRON, 15ml, Pkg 1	10/03/2022	37.36	1282.71	None	Single Source Drug	658485	None	American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3206/us-sobc-ver-10-01102022.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	There was no change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the acquisition fields: Injectafer is not an acquired product. The licensor has granted American Regent the right to develop, manufacture, distribute and sell the product in the United States. American Regent is the NDA holder of this NDC but markets the drug through our parent company, Daiichi Sankyo, Inc.
Rx0000128	American Regent	03/31/2022	00517074020	Methylergonovine Maleate Inj., 0.2MG/ML, 1ML VL, 20 PK	02/01/2022	22.60	586.60	None	Non-innovator Multiple Source Drug	24144	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	Methylergonovine Maleate is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517037405	ProvayBlue (Methylene Blue Injection), 50mg/10ml (5mg/ml), PKG OF 5	02/01/2022	112.30	1302.15	None	Single Source Drug	434640	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug ProvayBlue that is the subject of the report and therefore has left the patent expiration data element blank. ProvayBlue is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517231005	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 10ML, PKG. OF 5	02/01/2022	27.50	577.50	None	Single Source Drug	839845	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517232510	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 2.5ML, PKG. OF 10	02/01/2022	13.59	286.30	None	Single Source Drug	104030	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517234010	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 10	02/01/2022	27.50	577.50	None	Single Source Drug	3949570	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517234025	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 25	02/01/2022	68.75	1443.75	None	Single Source Drug	1283900	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000069	Amgen	03/31/2022	55513084301	Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector	01/26/2022	37.69	676.46	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513084301	Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector	07/01/2022	20.29	696.75	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513084101	Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector	01/26/2022	37.69	676.46	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513084101	Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector	07/01/2022	20.29	696.75	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513016001	Blincyto, 35 mcg lyophilized vial, 1 pk	01/26/2022	250.28	4492.38	04/06/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Blincyto reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513016001	Blincyto, 35 mcg lyophilized vial, 1 pk	07/01/2022	134.77	4627.15	04/06/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Blincyto reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513081328	Corlanor, 5mg oral solution AMP, 28 pk	01/26/2022	13.53	242.89	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513081328	Corlanor, 5mg oral solution AMP, 28 pk	07/01/2022	7.29	250.18	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2022	55513080060	Corlanor, 5mg tablet, 60 pk	01/26/2022	29.00	520.49	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	09/30/2022	55513080060	Corlanor, 5mg tablet, 60 pk	07/01/2022	15.61	536.10	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2022	55513081060	Corlanor, 7.5mg tablet, 60 pk	01/26/2022	29.00	520.49	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	09/30/2022	55513081060	Corlanor, 7.5mg tablet, 60 pk	07/01/2022	15.61	536.10	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2022	58406004401	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406004401	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406004404	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406004404	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406003201	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406003201	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406044501	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pk	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406044501	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pk	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406003204	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406003204	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406044504	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pk	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406044504	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pk	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406042534	Enbrel, 25mg (1 mL), Vial (EA), 4 pack	01/26/2022	220.82	3204.90	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406042534	Enbrel, 25mg (1 mL), Vial (EA), 4 pack	07/01/2022	76.92	3281.82	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406042541	Enbrel, 25mg (1mL), Vial (EA), 1 pack	01/26/2022	55.21	801.23	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406042541	Enbrel, 25mg (1mL), Vial (EA), 1 pack	07/01/2022	19.23	820.46	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406001001	Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack	01/26/2022	55.21	801.23	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406001001	Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack	07/01/2022	19.23	820.46	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406001004	Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack	01/26/2022	220.82	3204.90	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406001004	Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack	07/01/2022	76.92	3281.82	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406005501	Enbrel, 25mg/0.5mL, Vial (EA), 1 pack	01/26/2022	55.21	801.23	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406005501	Enbrel, 25mg/0.5mL, Vial (EA), 1 pack	07/01/2022	19.23	820.46	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406005504	Enbrel, 25mg/0.5mL, Vial (EA), 4 pack	01/26/2022	220.82	3204.90	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406005504	Enbrel, 25mg/0.5mL, Vial (EA), 4 pack	07/01/2022	76.92	3281.82	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406002101	Enbrel, 50mg/mL, Syringe (ML), 1 pack	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406002101	Enbrel, 50mg/mL, Syringe (ML), 1 pack	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406043501	Enbrel, 50mg/mL, Syringe (ML), 1 pk	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406043501	Enbrel, 50mg/mL, Syringe (ML), 1 pk	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406002104	Enbrel, 50mg/mL, Syringe (ML), 4 pack	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406002104	Enbrel, 50mg/mL, Syringe (ML), 4 pack	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406043504	Enbrel, 50mg/mL, Syringe (ML), 4 pk	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406043504	Enbrel, 50mg/mL, Syringe (ML), 4 pk	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513007801	Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial	01/26/2022	3.24	58.10	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513007801	Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial	07/01/2022	1.74	59.84	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513007901	Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial	01/26/2022	323.64	5809.03	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513007901	Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial	07/01/2022	174.27	5983.30	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	76075010301	Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk	01/26/2022	25.36	455.21	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	76075010301	Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk	07/01/2022	13.66	468.87	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	76075010201	Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk	01/26/2022	76.08	1365.64	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	76075010201	Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk	07/01/2022	40.97	1406.61	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	76075010101	Kyprolis, 60 mg lyophilized vial, 1 pk	01/26/2022	152.17	2731.28	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	76075010101	Kyprolis, 60 mg lyophilized vial, 1 pk	07/01/2022	81.94	2813.22	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513022301	Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial	01/26/2022	60.91	1093.26	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513022301	Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial	07/01/2022	32.80	1126.06	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513022101	Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial	01/26/2022	121.82	2186.50	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513022101	Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial	07/01/2022	65.60	2252.09	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513022201	Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial	01/26/2022	243.63	4372.99	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513022201	Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial	07/01/2022	131.19	4504.18	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	59572063255	Otezla, 10mg (4)-20mg (4)-30g (47) Tablet Dose Pack 55 pack	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2015	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	59572063255	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pk	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2015	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513013760	Otezla, 30mg, Tablet, 60 pack	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513013760	Otezla, 30mg, Tablet, 60 pack	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	59572063106	Otezla, 30mg, Tablet, 60 pk	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2014	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	59572063106	Otezla, 30mg, Tablet, 60 pk	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2014	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	01/26/2022	79.90	1434.14	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	07/01/2022	43.02	1477.16	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513095401	Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial	01/26/2022	80.16	1438.85	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513095401	Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial	07/01/2022	43.17	1482.02	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2022	55513095601	Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial	01/26/2022	320.65	5755.40	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513095601	Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial	07/01/2022	172.66	5928.06	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513073001	Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial	07/01/2022	79.14	2717.15	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000122	Amneal Pharmaceuticals	09/30/2022	53746066901	Acebutolol HCl Oral Capsule 200 MG 100	07/17/2022	12.93	77.93	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	09/30/2022	53746067001	Acebutolol HCl Oral Capsule 400 MG 100	07/17/2022	17.11	103.11	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066930	Emverm Oral Tablet Chewable 100 MG 1	02/01/2022	50.63	562.01	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	405.53	369.00	2017	369.00	None	None
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162011511	Hydrocodone Bitartrate & Acetaminophen 7.5mg-325mg Tablets 1000	12/24/2022	90.00	210.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162011550	Hydrocodone Bitartrate & Acetaminophen 7.5mg-325mg Tablets 500	12/24/2022	45.00	105.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148701	Mixed Amphetamine Sulfate Extended Release 10mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148801	Mixed Amphetamine Sulfate Extended Release 15mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148901	Mixed Amphetamine Sulfate Extended Release 20mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115149001	Mixed Amphetamine Sulfate Extended Release 25mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115149101	Mixed Amphetamine Sulfate Extended Release 30mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148601	Mixed Amphetamine Sulfate Extended Release 5mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846030115	Nizatidine Oral Solution 15 MG/ML 480	02/01/2022	55.18	612.59	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	Gemini	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	419.59	419.59	2018	419.59	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069701	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 100	02/01/2022	116.06	699.27	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	381.56	381.56	2013	278.45	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069713	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 60	02/01/2022	69.64	419.57	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	228.94	228.94	2013	167.07	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069801	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 100	02/01/2022	160.94	969.69	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	529.13	529.13	2013	386.15	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069813	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 60	02/01/2022	96.57	581.83	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	317.48	317.48	2013	231.69	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069901	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 100	02/01/2022	205.84	1240.22	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	676.74	676.74	2013	493.86	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069913	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 60	02/01/2022	123.51	744.14	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	406.05	406.05	2013	296.32	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070001	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 100	02/01/2022	296.28	1785.10	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	974.06	974.06	2013	710.84	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070013	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 60	02/01/2022	177.77	1071.07	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	584.44	584.44	2013	426.50	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070101	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 100	02/01/2022	386.71	2329.99	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	1271.39	1271.39	2013	927.82	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070113	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 60	02/01/2022	232.03	1398.00	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	762.84	762.84	2013	556.69	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069501	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 100	02/01/2022	60.44	364.16	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	198.71	198.71	2013	145.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069513	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 60	02/01/2022	36.26	218.48	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	119.22	119.22	2013	87.01	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069601	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 100	02/01/2022	88.24	531.68	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	290.12	290.12	2013	211.72	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069613	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 60	02/01/2022	52.95	319.01	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	174.07	174.07	2013	127.03	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066101	Rytary Oral Capsule Extended Release 23.75-95 MG 100	02/01/2022	34.65	384.70	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066201	Rytary Oral Capsule Extended Release 36.25-145 MG 100	02/01/2022	34.65	384.70	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066301	Rytary Oral Capsule Extended Release 48.75-195 MG 100	02/01/2022	34.65	384.70	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066401	Rytary Oral Capsule Extended Release 61.25-245 MG 100	02/01/2022	43.55	483.41	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	366.51	324.69	2015	289.00	None	None
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162055650	Temazepam 15mg Capsules 500	12/24/2022	33.00	60.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162055750	Temazepam 30mg Capsules 500	12/24/2022	35.35	70.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080501	Unithroid Oral Tablet 100 MCG 100	02/01/2022	33.43	371.15	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080601	Unithroid Oral Tablet 112 MCG 100	02/01/2022	33.50	371.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080701	Unithroid Oral Tablet 125 MCG 100	02/01/2022	33.56	372.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080801	Unithroid Oral Tablet 137 MCG 100	02/01/2022	33.59	372.91	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080901	Unithroid Oral Tablet 150 MCG 100	02/01/2022	33.62	373.21	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846081001	Unithroid Oral Tablet 175 MCG 100	02/01/2022	33.67	373.77	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846081101	Unithroid Oral Tablet 200 MCG 100	02/01/2022	33.70	374.12	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080101	Unithroid Oral Tablet 25 MCG 100	02/01/2022	33.25	369.06	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846081201	Unithroid Oral Tablet 300 MCG 100	02/01/2022	33.74	374.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080201	Unithroid Oral Tablet 50 MCG 100	02/01/2022	33.27	369.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080301	Unithroid Oral Tablet 75 MCG 100	02/01/2022	33.30	369.71	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080401	Unithroid Oral Tablet 88 MCG 100	02/01/2022	33.38	370.53	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2022	54436032530	Nocdurna 27.7 mcg sublingual tablets carton 30	01/01/2022	34.65	496.61	12/01/2025	Single Source Drug	5000	None	Costs due to product acquisition, supply and marketing costs	None	increased supply and demand	None	10/01/2020	Ferring Pharmaceuticals	8750000	None	None	461.96	420.00	2018	420.00	None	this was the only price increase in past 5 yrs listed in Medispan
Rx0000412	Antares Pharma, Inc	06/30/2022	54436032530	Nocdurna 27.7 mcg sublingual tablets carton 30	04/30/2022	34.65	496.61	04/13/2030	Single Source Drug	6500	None	marketing & acquisition costs	None	Increase in supply & demand	None	10/01/2020	Ferring Pharmaceuticals	17500000	None	None	461.96	461.96	2018	420.00	None	None
Rx0000412	Antares Pharma, Inc	03/31/2022	54436035030	Nocdurna 55.3 mcg sublingual tablets carton 30	01/01/2022	34.65	496.61	12/01/2025	Single Source Drug	6642	None	Costs due to product acquisition, supply and marketing costs	None	Increased supply and demand	None	10/01/2020	Ferring Pharmaceuticals	8750000	None	None	461.96	420.00	2018	420.00	None	only price increase
Rx0000412	Antares Pharma, Inc	06/30/2022	54436035030	Nocdurna 55.3 mcg sublingual tablets carton 30	04/30/2022	34.65	496.61	04/13/2030	Single Source Drug	8000	None	marketing & acquisition costs	None	Increase in supply & demand	None	10/01/2020	Ferring Pharmaceuticals	17500000	None	None	461.96	461.96	2018	420.00	None	None
Rx0000412	Antares Pharma, Inc	12/31/2022	54436011220	TLANDO (Testosterone Undecanoate) 112.5 mg. Capsules; 120 Capsules per bottle; dosing - 2 capsules B.I.D.	12/02/2022	48.65	743.65	04/28/2041	Single Source Drug	5000	None	Increased supply and distribution costs	None	Improved marketing of product	None	03/28/2022	Lipocine	21000000	None	None	695.00	0.00	2022	695.00	None	None
Rx0000271	Apotex Corp	12/31/2022	60505437703	PAXIL CR FCT 12.5MG 30BTL USA	10/28/2022	23.70	263.12	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505437803	PAXIL CR FCT 25MG 30BTL USA	10/28/2022	24.74	274.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505437903	PAXIL CR FCT 37.5MG 30BTL USA	10/28/2022	25.48	282.83	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505451703	PAXIL FCT 10MG 30BTL USA	10/28/2022	23.01	255.46	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505451803	PAXIL FCT 20MG 30BTL USA	10/28/2022	24.01	266.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505451903	PAXIL FCT 30MG 30BTL USA	10/28/2022	24.74	274.61	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505452003	PAXIL FCT 40MG 30BTL USA	10/28/2022	26.13	290.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505040205	PAXIL O/SUSP 10MG/5ML 250ML BTL USA1	10/28/2022	39.94	443.46	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000435	Aquestive Therapeutics	03/31/2022	10094021060	Sympazan Oral Film 10 MG	01/03/2022	256.80	1816.80	04/03/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000435	Aquestive Therapeutics	03/31/2022	10094022060	Sympazan Oral Film 20 MG	01/03/2022	513.60	3633.60	04/03/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000435	Aquestive Therapeutics	03/31/2022	10094020560	Sympazan Oral Film 5 MG	01/03/2022	128.40	908.40	04/03/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2022	24338001009	Bidil - Hydralazine Hydrochloride; Isosorbide Dinitrate 37.5mg;20mg Oral Tablet 90ct	10/01/2022	35.54	390.92	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2022	24338012603	Ery-Tab Delayed Release Oral Tablet (Erythromycin) 500mg 30ct	10/01/2022	54.76	396.98	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000075	Assertio Therapeutics, Inc.	03/31/2022	13913001203	Cambia (diclofenac potassium) 50MG Oral 9 Packets	02/01/2022	64.94	886.97	06/16/2026	Single Source Drug	None	1	"Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. "	None	NONE	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years.
Rx0000075	Assertio Therapeutics, Inc.	03/31/2022	13913000812	Zipsor (diclofenac potassium) 25MG Oral Capsule 120 Ct Bottle	02/01/2022	136.36	1862.39	02/24/2029	Single Source Drug	None	1	"Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. "	None	NONE	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years.
Rx0000058	Avanir Pharmaceuiticals	03/31/2022	64597030160	Nuedexta Oral Capsule 20-10 mg Bottles of 60 Capsules	01/01/2022	90.00	1425.00	08/13/2026	Single Source Drug	None	1	Avanir is committed to making responsible pricing determinations, and in so doing we consider a range of factors. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Avanir are made at the executive level in adherence with all federal and state laws.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	The reason for the blank acquisition-related fields is that Neudexta was not acquired.
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2022	75854060228	Balcoltra Oral Tablet 0.1-20 MG-MCG(21)	02/19/2022	20.03	245.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Product not acquired within last five years
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2022	75854060203	Balcoltra Oral Tablet 0.1-20 MG-MCG(21)1/17/2022	01/17/2022	60.07	734.99	06/01/2027	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Columns were left blank because this product was not acquired within the last 5 years.
Rx0000108	AvKare	12/31/2022	42291096218	Estradiol Vaginal Insert 10mcg Tab - 18ct	10/05/2022	20.95	140.67	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	12/31/2022	42291096208	Estradiol Vaginal Insert 10mcg Tab - 8ct	10/05/2022	9.12	62.81	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	12/31/2022	42291049530	Lidocaine Patches 5% - 30ct	11/15/2022	12.74	55.57	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628008003	FIRST Lansoprazole 3mg/mL 3 oz Suspension Compounding Kit	05/01/2022	30.00	115.00	None	Single Source Drug	3584220	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628008005	FIRST Lansoprazole 3mg/mL 5 oz Suspension Compounding Kit	05/01/2022	20.00	115.00	None	Single Source Drug	2890560	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628008010	FIRST Lansoprazole Powder 10 oz 300mL 3mg/mL Oral Suspension	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628008003	FIRST Lansoprazole Powder 3 oz 90mL 3mg/mL Oral Suspension	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628008005	FIRST Lansoprazole Powder 5 oz 150mL 3mg/mL Oral Suspension	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628007010	FIRST Omeprazole 10 oz 300ml Suspension Kit 2mg/mL	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628007003	FIRST Omeprazole 2mg/ml 3 oz Suspension Compounding Kit	05/01/2022	30.00	115.00	None	Single Source Drug	7507200	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628007005	FIRST Omeprazole 2mg/ml 5 oz Suspension Compounding Kit	05/01/2022	20.00	115.00	None	Single Source Drug	7225260	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628007003	FIRST Omeprazole 3 oz 90ML Suspension Kit	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628007005	FIRST Omeprazole 5 oz 150mL Suspension Kit 2mg/mL	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264959420	0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTION, Injectable, 400mg/100mL, 250ml bag, 24 bags per case	08/01/2022	38.25	175.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264959410	0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTION, Injectable, 400mg/100mL, 500mL bag, 24 bags per case	08/01/2022	13.61	200.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264959820	0.8% LIDOCAINE HCL AND DEXTROSE INJECTION, Injectable, 800mg/100mL, 250mL bag, 24 bags per case	08/01/2022	12.39	182.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264180032	0.9% SODIUM CHLORIDE INJECTION USP, Injectable, 900 mg/mL, 100mL bag, 64 bags per case	08/01/2022	13.44	158.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264180036	0.9% SODIUM CHLORIDE INJECTION USP, Injectable, 900 mg/mL, 25mL bag, 116 bags per case	08/01/2022	46.77	291.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264180031	0.9% SODIUM CHLORIDE INJECTION USP, Injectable, 900 mg/mL, 50mL bag, 84 bags per case	08/01/2022	17.64	208.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264762320	10% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP Injectable, 10gm/100mL Dextrose; 200mg/100mL Sodium Chloride, 250mL bag, 24 bags per case	08/01/2022	6.92	81.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264762200	10% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP, Injectable, 10gm/100mL Dextrose; 450mg/100mL Sodium Chloride, 1000mL bag, 12 bags per case	08/01/2022	8.12	95.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264752000	10% DEXTROSE INJECTION USP, Injectable, 10gm/100mL, 1000mL bag, 12 bags per case	08/01/2022	28.94	66.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264752020	10% DEXTROSE INJECTION USP, Injectable, 10gm/100mL, 250mL bag, 24 bags per case	08/01/2022	37.07	88.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264752010	10% DEXTROSE INJECTION USP, Injectable, 10gm/100mL, 500mL bag, 24 bags per case	08/01/2022	30.09	96.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264761620	5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP, Injectable, 5gm/100mL Dextrose; 220mg/100mL Sodium Chloride, 250mL bag, 24 bags per case	08/01/2022	39.23	90.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264751020	5% DEXTROSE INJECTION USP, Injectable, 5gm/100mL, 250mL bag, 24 bags per case	08/01/2022	6.41	74.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264751010	5% DEXTROSE INJECTION USP, Injectable, 5gm/100mL, 500mL bag, 24 bags per case	08/01/2022	6.85	81.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264310311	CEFAZOLIN 1G 50ML ISO-OSMOTIC DEXINJ DUPLEX DRUG DEL SYSTEM, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	19.68	292.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264310511	CEFAZOLIN FOR INJECTION USP AND DEXTROSE INJECTION USP IN THE, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	30.75	337.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264319311	CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, Injectable, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	40.92	449.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264319511	CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, Injectable, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	98.88	681.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264312311	CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINER, Injectable, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	28.43	420.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264312511	CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINER, Injectable, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	50.73	752.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264314511	CEFTAZIDIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, Injectable, Eq 2gm base/vial, 50mL bag, 24 bags per case	08/01/2022	38.15	565.92	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264315311	CEFTRIAXONE FOR INJECTION AND DEXTROSE INJECTION IN DUPLEX, Injectable, Eq 1gm base/vial, 50mL bag, 24 bags per case	08/01/2022	29.64	438.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264957710	HEPARIN IN DEXTROSE INJECTION, Injectable, 4,000 Units/100mL, 500mL bag, 24 bags per case	08/01/2022	25.56	379.68	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264956710	HEPARIN SODIUM IN 5% DEXTROSE INJECTION (500 U/ML), Injectable, 5,000 Units/100mL, 500mL bag, 24 bags per case	08/01/2022	21.72	321.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264318311	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER 0.5G, Powder, 500mg/vial, 50mL bag, 24 bags per case	08/01/2022	42.62	468.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264318511	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER 1 G, Powder, 1gm/vial, 50mL bag, 24 bags per case	08/01/2022	103.73	699.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264553532	METRO IV (METRONIDAZOLE INJECTION 0.5%), Injectable, 500mg/100mL, 100mL bag, 24 bags per case	08/01/2022	5.30	76.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264446030	NUTRILIPID 20%, Injectable, 20%, 250mL bag, 12 bags per case	08/01/2022	27.35	282.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264446010	NUTRILIPID 20%, Injectable, 20%, 500mL bag, 12 bags per case	08/01/2022	34.61	358.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738860	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, Solution, 900mg/100mL, 3000mL, 4 bags per case	08/01/2022	4.54	66.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738550	STERILE WATER FOR INJECTION USP, Liquid, 100%, 2000mL bag, 4 bags per case	08/01/2022	12.34	44.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738560	STERILE WATER FOR INJECTION USP, Liquid, 100%, 3000mL bag, 4 bags per case	08/01/2022	12.57	52.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264785000	STERILE WATER FOR INJECTION USP, Liquid, 100%1000mL, 1000mL bag, 12 bags per case	08/01/2022	6.19	47.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738650	STERILE WATER FOR IRRIGATION USP, Liquid, 100%, 2000mL bag, 4 bags per case	08/01/2022	13.93	54.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2022	00264738660	STERILE WATER FOR IRRIGATION USP, Liquid, 100%, 3000mL bag, 4 bags per case	08/01/2022	4.74	70.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035310	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL	01/01/2022	30.13	532.30	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035305	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL	01/01/2022	15.07	266.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208062901	BEPREVE™ Ophthalmic Solution USP, 1.5%, 10mL	01/01/2022	27.72	489.82	01/13/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208062902	BEPREVE™ Ophthalmic Solution USP, 1.5%, 5mL	01/01/2022	14.50	256.11	01/13/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208044605	BESIVANCE® (besifloxacin ophthalmic suspension 0.6%), 5mL	01/01/2022	11.42	201.71	01/09/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208080060	LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg, 60 Sterile Ophthalmic Inserts	01/01/2022	33.80	597.13	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050307	LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%), 5g	01/01/2022	12.86	227.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208044335	LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%), 3.5g	01/01/2022	18.09	319.64	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208029910	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL	01/01/2022	32.05	566.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208029915	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL	01/01/2022	47.65	841.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208029905	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL	01/01/2022	16.03	283.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050707	LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%, 5g	01/01/2022	12.86	227.16	12/23/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208060203	PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL	01/01/2022	17.98	317.61	11/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208081425	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL	01/01/2022	13.72	242.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208081605	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL	01/01/2022	15.04	265.75	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050402	VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 2.5mL	01/01/2022	12.87	227.25	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208050405	VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 5mL	01/01/2022	25.72	454.49	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208053535	ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%), 5mL	01/01/2022	23.68	418.36	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035810	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL	01/01/2022	33.35	589.31	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2022	24208035805	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL	01/01/2022	16.68	294.65	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187581030	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct	01/01/2022	126.89	1733.16	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187581130	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct	01/01/2022	167.28	2284.74	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187581230	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct	01/01/2022	380.68	5199.39	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006410	ATIVAN® Tablets 1mg 1,000s	01/01/2022	2974.12	40621.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006301	ATIVAN® Tablets .5mg 100s	01/01/2022	227.32	3104.86	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006401	ATIVAN® Tablets 1mg 100s	01/01/2022	303.68	4147.65	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187006501	ATIVAN® Tablets 2mg 100s	01/01/2022	483.97	6610.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187000201	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 100g	01/01/2022	26.97	476.41	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187000260	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 60g	01/01/2022	16.18	285.84	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	25010030515	DEMSER® (metyrosine), 250mg Capsules, 100ct	01/01/2022	3085.63	42144.28	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187540004	JUBLIA® (efinaconazole) Topical Solution 10%, 4mL	01/01/2022	38.62	682.24	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187540008	JUBLIA® (efinaconazole) Topical Solution 10%, 8mL	01/01/2022	77.24	1364.48	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187301220	MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle	01/01/2022	110.09	1503.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187301030	MESTINON 60mg TABLETS 100s (pyridostigmine bromide)	01/01/2022	135.54	1851.16	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187301330	MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT	01/01/2022	77.12	1053.33	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	66490069110	MYSOLINE 250 mg TABLETS, 100s (primidone)	01/01/2022	435.62	5949.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	66490069010	MYSOLINE 50 mg TABLETS, 100s (primidone)	01/01/2022	126.59	1728.97	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187305050	ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump	01/01/2022	37.70	665.97	08/05/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187442010	PEPCID® (Famotidine) Tablets, 20mg, 100	01/01/2022	96.82	1322.35	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187442030	PEPCID® (Famotidine) Tablets, 20mg, 30	01/01/2022	29.04	396.71	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187444010	PEPCID® (Famotidine) Tablets, 40mg, 100	01/01/2022	187.14	2555.89	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187444030	PEPCID® (Famotidine) Tablets, 40mg, 30	01/01/2022	56.14	766.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187000402	SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)	01/01/2022	389.33	4321.93	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187149825	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL, 60ct	01/01/2022	28.20	498.17	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187149605	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL, 60ct	01/01/2022	32.16	568.08	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014090	VASOTEC® 2.5mg Tablets, 90s	01/01/2022	106.29	1451.73	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014210	VASOTEC® 10mg Tablets, 1,000s	01/01/2022	1506.49	20576.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014230	VASOTEC® 10mg Tablets, 30s	01/01/2022	45.19	617.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014290	VASOTEC® 10mg Tablets, 90s	01/01/2022	135.60	1852.02	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014030	VASOTEC® 2.5mg Tablets, 30s	01/01/2022	35.43	483.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014310	VASOTEC® 20mg Tablets, 1,000s	01/01/2022	2143.54	29276.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014330	VASOTEC® 20mg Tablets, 30s	01/01/2022	64.31	878.37	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014390	VASOTEC® 20mg Tablets, 90s	01/01/2022	192.93	2635.02	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014130	VASOTEC® 5mg Tablets, 30s	01/01/2022	41.10	561.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187014190	VASOTEC® 5mg Tablets, 90s	01/01/2022	123.27	1683.68	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187073030	WELLBUTRIN® XL 150mg Tablets, 30ct	01/01/2022	125.29	1711.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187073090	WELLBUTRIN® XL 150mg Tablets, 90ct	01/01/2022	375.88	5133.82	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187073130	WELLBUTRIN® XL 300mg Tablets, 30ct	01/01/2022	165.38	2258.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2022	00187045302	ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct	01/01/2022	382.93	5230.21	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000024	Bayer	03/31/2022	50419025091	ADEMPAS 0.5 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025001	ADEMPAS 0.5 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025191	ADEMPAS 1 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025101	ADEMPAS 1 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025291	ADEMPAS 1.5 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025201	ADEMPAS 1.5 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025391	ADEMPAS 2 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025301	ADEMPAS 2 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025491	ADEMPAS 2.5 MG TABLET 9 count	01/01/2022	69.66	1231.20	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2022	50419025401	ADEMPAS 2.5 MG TABLET 90 count	01/01/2022	696.60	12312.00	02/18/2034	Single Source Drug	None	1	None	1	Information not publicly available.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2022	50419048858	Nexavar 200mg 120 Tablets	05/26/2022	621.60	22814.40	09/10/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2022	50419017101	Stivarga 40 mg tab 28 count bottle	05/26/2022	262.08	6817.44	06/02/2030	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2022	50419017103	Stivarga 40 mg tab 3x28 count bottle	05/26/2022	786.24	20452.32	06/02/2030	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000483	Benuvia Operations, LLC	12/31/2022	78613020130	Syndros (dronabinol) oral solution, CII 5 mg/mL - 1 Bottle	12/20/2022	583.33	1749.99	08/06/2028	Single Source Drug	None	1	None	1	None	1	08/24/2022	Benuvia, Inc.	None	1	None	1166.66	1166.66	2017	973.00	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=671	None
Rx0000099	Biogen	03/31/2022	64406000801	TYSABRI (natalizumab) Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial	01/01/2022	391.85	7855.84	03/05/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tysabri was not acquired by Biogen from another company in the last 5 years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014130	GILOTRIF 20MG TABLET 30	01/10/2022	403.30	10485.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=622	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597013730	GILOTRIF 30MG TABLET 30	01/10/2022	403.30	10485.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=617	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597013830	GILOTRIF 40MG TABLET 30	01/10/2022	403.30	10485.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=618	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015230	JARDIANCE 10MG TABLET 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=631	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015237	JARDIANCE 10MG TABLET 3x10	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=632	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015290	JARDIANCE 10MG TABLET 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=633	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015330	JARDIANCE 25MG TABLET 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=634	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015337	JARDIANCE 25MG TABLET 3x10	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=635	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015390	JARDIANCE 25MG TABLET 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=636	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014818	JENTADUETO 2.5MG-1000MG Tablet 180	01/10/2022	58.27	1514.64	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=629	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014860	JENTADUETO 2.5MG-1000MG Tablet 60	01/10/2022	19.42	504.88	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=630	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014618	JENTADUETO 2.5MG-500MG Tablet 180	01/10/2022	58.27	1514.64	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=625	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014660	JENTADUETO 2.5MG-500MG Tablet 60	01/10/2022	19.42	504.88	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=626	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014718	JENTADUETO 2.5MG-850MG Tablet 180	01/10/2022	58.27	1514.64	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=627	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014760	JENTADUETO 2.5MG-850MG Tablet 60	01/10/2022	19.42	504.88	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=628	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027094	JENTADUETO XR 2.5MG-1000MG Tablet 180	01/10/2022	58.27	1514.64	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=648	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027073	JENTADUETO XR 2.5MG-1000MG Tablet 60	01/10/2022	19.42	504.88	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=647	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027533	JENTADUETO XR 5MG-1000MG Tablet 30	01/10/2022	19.42	504.88	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=649	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597027581	JENTADUETO XR 5MG-1000MG Tablet 90	01/10/2022	58.27	1514.64	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=650	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014360	OFEV 100MG CAPSULE 60	01/10/2022	444.54	11558.14	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=623	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2022	00597014360	OFEV 100MG CAPSULE 60	07/01/2022	222.28	11780.42	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014560	OFEV 150MG CAPSULE 60	01/10/2022	444.54	11558.14	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=624	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2022	00597014560	OFEV 150MG CAPSULE 60	07/01/2022	222.28	11780.42	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597019705	PRAXBIND 2.5g/50mL Vials 2	01/10/2022	171.17	4450.43	07/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=646	For Column F, this drug is not listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), and there are no patents listed in the FDA database “Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations”. Patent expiration is provided from the Orange Book listing for an associated drug. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597007541	SPIRIVA HANDIHALER 18mcg Blister Card 30	01/10/2022	19.12	497.12	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=613	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597007575	SPIRIVA HANDIHALER 18mcg Blister Card 5	01/10/2022	3.79	98.46	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=615	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597007547	SPIRIVA HANDIHALER 18mcg Blister Card 90	01/10/2022	57.35	1491.36	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=614	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597016061	SPIRIVA RESPIMAT 1.25mcg Cartridge 4	01/10/2022	19.12	497.12	04/16/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=639	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597010061	SPIRIVA RESPIMAT 2.5mcg Cartridge 4	01/10/2022	19.12	497.12	04/16/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=616	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597016818	SYNJARDY 12.5-1000MG Tablet 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=640	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597016860	SYNJARDY 12.5-1000MG Tablet 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=641	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597018018	SYNJARDY 12.5-500MG Tablet 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=644	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597018060	SYNJARDY 12.5-500MG Tablet 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=645	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597017518	SYNJARDY 5-1000MG Tablet 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=642	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597017560	SYNJARDY 5-1000MG Tablet 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=643	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015918	SYNJARDY 5-500MG TABLET 180	01/10/2022	65.83	1711.44	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=637	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597015960	SYNJARDY 5-500MG TABLET 60	01/10/2022	21.94	570.48	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=638	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597028073	SYNJARDY XR 10mg-1000mg Tablet 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=651	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597028090	SYNJARDY XR 10mg-1000mg Tablet 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=652	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597030093	SYNJARDY XR 12.5mg-1000mg Tablet 180	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=658	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597030045	SYNJARDY XR 12.5mg-1000mg Tablet 60	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=657	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029588	SYNJARDY XR 25mg-1000mg Tablet 30	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=656	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029578	SYNJARDY XR 25mg-1000mg Tablet 90	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=655	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029059	SYNJARDY XR 5mg-1000mg Tablet 180	01/10/2022	65.83	1711.44	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=653	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597029074	SYNJARDY XR 5mg-1000mg Tablet 60	01/10/2022	21.94	570.48	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=654	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014061	TRADJENTA 5MG TABLET 100	01/10/2022	64.74	1682.93	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=620	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014030	TRADJENTA 5MG TABLET 30	01/10/2022	19.42	504.88	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=619	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2022	00597014090	TRADJENTA 5MG TABLET 90	01/10/2022	58.27	1514.64	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=621	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089321	ELIQUIS 2.5 MG Tablet, Bottle of 60 Tablets	01/01/2022	29.94	529.01	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089331	ELIQUIS 2.5 MG Tablet, Bottle x 100 Tablets	01/01/2022	49.91	881.76	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089470	ELIQUIS 5 MG Tablet Bottle of 74 Tablets	01/01/2022	36.93	652.46	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003376474	ELIQUIS 5 MG Tablet, 74 Tablets (1 blister pack of 42 tabs and 1 blister pack of 32 tabs)	01/01/2022	36.93	652.46	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089421	ELIQUIS 5 MG Tablet, Bottle of 60 Tablets	01/01/2022	29.94	529.01	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2022	00003089431	ELIQUIS 5 MG Tablet, Hospital Unit-Dose, Blister Package of 100	01/01/2022	49.91	881.76	02/24/2031	Single Source Drug	None	1	"We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply."	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2022	00003218713	ORENCIA 250 MG Intravenous Solution, 1 Vial	07/01/2022	30.52	1301.99	12/19/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000064	CASPER PHARMA, LLC	03/31/2022	70199002611	Intramuscular Solution 50000 UNIT/ML (Package size - 2ML single dose vial)	01/25/2022	455.00	575.00	None	Single Source Drug	None	1	Casper Pharma makes pricing decisions regarding the WAC price of a medication after careful consideration of a number of factors, including but not limited to a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) overall general administration, research and development costs.	None	None	1	06/29/2018	Pfizer	None	1	None	100.00	100.00	2006	221.35	None	None
Rx0000110	Chartwell Rx LLC	03/31/2022	62135019222	Calcium Acetate Oral Tablet 667 MG 200 Tablet Bottles	01/03/2022	159.64	300.00	None	Non-innovator Multiple Source Drug	None	1	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	12/01/2019	Cipla	None	1	None	140.36	140.36	2019	140.36	None	The information contained in this report is subject to the following limitations and assumptions:  Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner.  Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs.  In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	09/30/2022	62135020690	methIMAzole Oral Tablet 10 MG 90ct	08/31/2022	110.14	270.00	None	Non-innovator Multiple Source Drug	4464	None	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/04/2021	CASI PHARMACEUTICALS	None	1	None	159.86	159.86	2001	159.86	None	The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	09/30/2022	62135020618	methIMAzole Oral Tablet 10 MG, 180ct	08/31/2022	220.28	540.00	None	Non-innovator Multiple Source Drug	1800	None	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/04/2021	CASI PHARMACEUTICALS	None	1	None	319.72	319.72	2001	319.72	None	The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	09/30/2022	62135020518	methIMAzole Oral Tablet 5 MG, 180ct	08/31/2022	309.97	495.00	None	Non-innovator Multiple Source Drug	4608	None	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/04/2021	CASI PHARMACEUTICALS	None	1	None	185.03	185.03	2001	185.03	None	The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	09/30/2022	62135020590	methIMAzole Oral Tablet 5 MG, 90ct	08/31/2022	154.98	247.50	None	Non-innovator Multiple Source Drug	9144	None	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/04/2021	CASI PHARMACEUTICALS	None	1	None	92.52	92.52	2001	92.52	None	The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 10/21/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column V-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner. Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs. In order to submit this report, a value above zero must be entered. Therefore, columns V - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	03/31/2022	62135096001	Sulfasalazine Oral Tablet 500 MG 100 Tablet Bottles	01/12/2022	100.00	200.00	None	Non-innovator Multiple Source Drug	None	1	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/01/2020	AVET/Heritage	None	1	None	100.00	100.00	2021	100.00	None	The information contained in this report is subject to the following limitations and assumptions:  Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner.  Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs.  In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	03/31/2022	62135096010	Sulfasalazine Oral Tablet 500 MG 1000 Tablet Bottles	01/12/2022	1000.00	2000.00	None	Non-innovator Multiple Source Drug	None	1	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/01/2020	AVET/Heritage	None	1	None	1000.00	1000.00	2021	1000.00	None	The information contained in this report is subject to the following limitations and assumptions:  Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner.  Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs.  In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	03/31/2022	62135096031	Sulfasalazine Oral Tablet 500 MG 300 Tablet Bottles	01/12/2022	300.00	600.00	None	Non-innovator Multiple Source Drug	None	1	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/01/2020	AVET/Heritage	None	1	None	300.00	300.00	2021	300.00	None	The information contained in this report is subject to the following limitations and assumptions:  Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner.  Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs.  In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000110	Chartwell Rx LLC	03/31/2022	62135096005	Sulfasalazine Oral Tablet 500 MG 500 Tablet Bottles	01/12/2022	500.00	1000.00	None	Non-innovator Multiple Source Drug	None	1	Chartwell considers a number of factors in its pricing decisions, including increases in operating costs, inflation, and changes in the market.	None	The price increase was not necessitated by a change or improvement in the drug.	None	11/01/2020	AVET/Heritage	None	1	None	500.00	500.00	2021	500.00	None	The information contained in this report is subject to the following limitations and assumptions:  Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chartwell believes is otherwise in the public domain or publicly available. (Column I) Patent Expiration Date is limited to data available in the FDA Orange Book as of 4/1/2022 which does not contain any unexpired patents for this product, therefore, Chartwell has left patent expiration field blank. (Column S-W) WAC at Acquisition and WAC Year Prior to Acquisition are unavailable. Chartwell acquired this ANDA file from the prior owner on the Acquisition Date stated in Column Q. At the time of acquisition and in years prior, ANDA was no longer actively marketed by the prior owner.  Chartwell did not assume marketing functions from prior owner, and did not receive any historical data from the sellers of the ANDAs.  In order to submit this report, a value above zero must be entered. Therefore, columns S - W report the WAC at Introduction, as this is the only WAC information available to Chartwell, despite its best efforts.
Rx0000139	Chiesi USA	03/31/2022	10122051001	Curosurf® 1.5ml 120 mg/1.5 mL (80 mg/mL)	02/01/2022	14.82	508.70	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired.
Rx0000139	Chiesi USA	03/31/2022	10122051003	Curosurf® 3.0ml 240 mg/3 mL (80 mg/mL)	02/01/2022	29.22	1003.10	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired.
Rx0000320	CMP Pharma	12/31/2022	46287002004	CaroSpir, Suspension, Oral, 25mg/5mL, 118 mL in 1 BOTTLE	10/17/2022	34.35	415.50	10/28/2036	Single Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2022	46287002001	CaroSpir, Suspension, Oral, 25mg/5mL, 473 mL in 1 BOTTLE	10/17/2022	137.15	1665.00	10/28/2036	Single Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2022	46287001430	Oracit, Cirtic Acid and Sodium Citrate, 640mg/5mL, Solution, Oral 10 Bottle Unit Dose in 1 Carton > 30 mL in 1 Bottle	10/17/2022	5.80	44.20	None	Non-innovator Multiple Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2022	46287002410	POTASSIUM PHOSPHATES, Injection, 300 mg/mL, 175 mg/mL, 10 VIAL, in 1 CARTON > 15 mL in 1 VIAL	12/01/2022	168.00	299.00	04/19/2039	Single Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2022	46287000660	Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 10 BOTTLE in 1 CARTON 60 mL in 1 BOTTLE,	12/01/2022	42.00	243.00	None	Non-innovator Multiple Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2022	46287000604	Sodium Polystyrene Sulfonate, suspension, 15g/60mL, 120 mL in 1 BOTTLE	12/01/2022	18.08	108.48	None	Non-innovator Multiple Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2022	46287000601	Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 473 mL in 1 BOTTLE	12/01/2022	44.52	196.52	None	Non-innovator Multiple Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510011660	NUCYNTA ER, 100mg, tablet, 60 pack	01/01/2022	137.73	1055.90	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	835.46	760.20	2011	269.40	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510017460	NUCYNTA ER, 150mg, tablet, 60 pack	01/01/2022	177.69	1362.29	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1077.89	980.79	2011	346.80	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510023260	NUCYNTA ER, 200mg, tablet, 60 pack	01/01/2022	225.57	1729.35	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1368.32	1245.06	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510029160	NUCYNTA ER, 250mg, tablet, 60 pack	01/01/2022	282.21	2163.60	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1711.91	1557.70	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510005860	NUCYNTA ER, 50mg, tablet, 60 pack	01/01/2022	74.47	570.93	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	451.74	411.05	2011	145.80	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510010010	NUCYNTA, 100mg, tablet, 100 pack	01/01/2022	179.47	1375.96	06/27/2025	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1088.71	990.64	2009	265.00	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510005010	NUCYNTA, 50mg, tablet, 100 pack	01/01/2022	115.25	883.59	06/27/2025	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	699.13	636.15	2009	170.00	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510007510	NUCYNTA, 75mg, tablet, 100 pack	01/01/2022	134.66	1032.39	06/27/2025	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	816.86	743.28	2009	199.00	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510011510	XTAMPZA ER, 13.5mg, capsule, 100 pack	01/01/2022	78.44	870.73	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510012010	XTAMPZA ER, 18mg, capsule, 100 pack	01/01/2022	99.47	1104.23	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510013010	XTAMPZA ER, 27mg, capsule, 100 pack	01/01/2022	138.37	1536.08	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510014010	XTAMPZA ER, 36mg, capsule, 100 pack	01/01/2022	170.32	1890.68	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2022	24510011010	XTAMPZA ER, 9mg, capsule, 100 pack	01/01/2022	53.29	591.60	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	03/31/2022	00713016612	MIGERGOT (Ergotamine Tartrate and Caffeine) Suppository, 2mg/100mg	01/28/2022	185.20	2039.10	None	Single Source Drug	3360	None	Operating primarily as a manufacturer of generic and over-the-counter drug products, Cosette Pharmaceuticals has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, Cosette carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, Cosette is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio.	None	1	None	06/28/2019	Horizon Therapeutics PLC	None	1	non-Public	842.76	766.80	1983	0.01	None	WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W.
Rx0000062	Covis Pharma	03/31/2022	00310080039	Tudorza Pressair, 1 POUCH IN 1 CARTON > 1 INHALER IN 1 POUCH > 30 POWDER, METERED IN 1 INHALER, 400 mcg	02/01/2022	25.72	311.46	03/13/2029	Single Source Drug	None	1	Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	01/04/2022	AstraZeneca Pharmaceuticals LP	None	1	None	285.74	285.74	2015	140.70	None	None
Rx0000062	Covis Pharma	03/31/2022	00310080060	Tudorza Pressair, 1 POUCH IN 1 CARTON > 1 INHALER IN 1 POUCH > 60 POWDER, METERED IN 1 INHALER, 400 mcg	02/01/2022	51.43	622.91	03/13/2029	Single Source Drug	None	1	Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	01/04/2022	AstraZeneca Pharmaceuticals LP	None	1	None	571.48	571.48	2015	281.40	None	None
Rx0000425	CSL Behring LLC	09/30/2022	44206045291	Hizentra 10 ml (2g) - inner 2gm Solution UOM=1 EA vial	07/01/2022	12.02	412.42	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2022	44206045202	Hizentra 10 ml (2g) 2gm Solution UOM=1 EA vial	07/01/2022	12.02	412.42	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2022	44206045492	Hizentra 20 ml (4g) - inner 4gm Solution UOM=1 EA vial	07/01/2022	24.04	824.84	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2022	44206045404	Hizentra 20 ml (4g) 4gm Solution UOM=1 EA vial	07/01/2022	24.04	824.84	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2022	44206045190	Hizentra 5 ml (1g) - inner 1gm Solution UOM=1 EA vial	07/01/2022	6.01	206.21	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2022	44206045101	Hizentra 5 ml (1g) 1gm Solution UOM=1 EA vial	07/01/2022	6.01	206.21	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2022	44206045593	Hizentra 50 ml (10g) - inner 10gm Solution UOM=1 EA vial	07/01/2022	42.10	2062.10	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2022	44206045510	Hizentra 50 ml (10g) 10gm Solution UOM=1 EA vial	07/01/2022	42.10	2062.10	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000230	Cumberland Pharmaceuticals	03/31/2022	66220028422	CALDOLOR, ready-to-use polypropylene flexible bag, 800 mg/200 mL, carton of 20 bags	01/20/2022	25.36	441.94	03/16/2032	Single Source Drug	115380	None	Increase in Cost of goods manufacture.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000230	Cumberland Pharmaceuticals	03/31/2022	66220028708	CALDOLOR, single-dose vial, 800 mg/8 mL, tray of 25 vials	01/20/2022	38.62	521.41	09/14/2030	Single Source Drug	106300	None	Increase in Cost of goods manufactured	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000230	Cumberland Pharmaceuticals	03/31/2022	66220031511	VIBATIV, single-dose vial, 750 mg, 1 vial	01/20/2022	16.18	555.46	01/01/2027	Single Source Drug	28318	None	Increase in Cost of Goods manufacture.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000181	Currax Pharmaceuticals LLC	03/31/2022	51267089099	Contrave Oral Tablet 120ct (naltrexome HCI/bupropion HCI) 8-90mg	03/03/2022	321.60	625.20	07/02/2024	Single Source Drug	None	1	None	1	None	1	09/27/2019	Nalpropion Pharmaceuticals LLC	None	None	The same private equity investor owned Currax Pharmaceuticals LLC and Nalpropion Pharmaceuticals LLC and merged the two companies.	277.99	277.99	2014	199.50	None	None
Rx0000114	Eli Lilly and Company	03/31/2022	00002473230	Olumiant Package Size: 30 Strength: 1 mg Dosage Form: TABLET	01/01/2022	118.80	2497.20	06/08/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Olumiant and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Olumiant. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002418230	Olumiant Package Size: 30 Strength: 2 mg Dosage Form: TABLET	01/01/2022	118.80	2497.20	06/08/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Olumiant and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Olumiant. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002144511	Taltz Package Size: 1 Strength: 80 mg/mL Dosage Form: AUTO-INJECTOR	01/01/2022	298.40	6272.80	02/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002772411	Taltz Package Size: 1 Strength: 80 mg/mL Dosage Form: SYRINGE	01/01/2022	298.40	6272.80	02/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002144527	Taltz Package Size: 2 Strength: 80 mg/mL Dosage Form: AUTO-INJECTOR	01/01/2022	596.80	12545.60	02/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002144509	Taltz Package Size: 3 Strength: 80 mg/mL Dosage Form: AUTO-INJECTOR	01/01/2022	895.20	18818.40	02/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002143380	Trulicity Package Size: 4 Strength: 0.75 mg/0.5 mL Dosage Form: PEN INJECTOR	01/01/2022	42.20	886.56	12/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Trulicity and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Trulicity. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002143480	Trulicity Package Size: 4 Strength: 1.5 mg/0.5 mL Dosage Form: PEN INJECTOR	01/01/2022	42.20	886.56	12/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Trulicity and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Trulicity. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002481554	Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET	01/10/2022	179.48	3444.00	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002533754	Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET	01/10/2022	179.48	3444.00	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002621654	Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET	01/10/2022	179.48	3444.00	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2022	00002448354	Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET	01/10/2022	179.48	3444.00	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000079	EMD Serono, Inc.	03/31/2022	44087122501	Cetrotide® (cetrorelix acetate for injection) Subcutaneous Kit 0.25 MG	01/25/2022	16.32	267.35	07/12/2021	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087907001	Gonal-f® Multi-Dose (follitropin alfa for injection) Injection Solution Reconstituted 1050 UNIT	01/25/2022	192.39	3152.57	08/23/2019	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087903001	Gonal-f® Multi-Dose (follitropin alfa for injection) Injection Solution Reconstituted 450 UNIT	01/25/2022	82.45	1351.10	08/23/2019	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087900501	Gonal-f® RFF* (follitropin alfa for injection) Subcutaneous Solution Reconstituted 75 UNIT -01 *Revised Formulation Female	01/25/2022	13.74	225.18	06/16/2015	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087900506	Gonal-f® RFF* (follitropin alfa for injection) Subcutaneous Solution Reconstituted 75 UNIT -10 *Revised Formulation Female	01/25/2022	137.42	2251.84	06/16/2015	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087111501	Gonal-f® RFF* Redi-ject™ (follitropin alfa for injection) Rediject Subcutaneous Solution Pen-injector 300 UNIT/0.5ML *Revised Formulation Female	01/25/2022	54.96	900.73	04/02/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087111601	Gonal-f® RFF* Redi-ject™ (follitropin alfa for injection) Rediject Subcutaneous Solution Pen-injector 450 UNT/0.75ML *Revised Formulation Female	01/25/2022	82.45	1351.10	04/02/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087111701	Gonal-f® RFF* Redi-ject™ (follitropin alfa for injection) Rediject Subcutaneous Solution Pen-injector 900 UNIT/1.5ML *Revised Formulation Female	01/25/2022	164.90	2702.20	04/02/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	06/30/2022	44087400000	Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG	04/06/2022	5174.60	91418.90	10/16/2026	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	06/30/2022	44087400004	Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG	04/06/2022	2069.84	36567.56	10/16/2026	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	06/30/2022	44087400005	Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG	04/06/2022	2587.30	45709.45	10/16/2026	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	06/30/2022	44087400006	Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG	04/06/2022	3104.76	54851.34	10/16/2026	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	06/30/2022	44087400007	Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG	04/06/2022	3622.22	63993.23	10/16/2026	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	06/30/2022	44087400008	Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG	04/06/2022	4139.68	73135.12	10/16/2026	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	06/30/2022	44087400009	Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG	04/06/2022	4657.14	82277.01	10/16/2026	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2022	44087115001	Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Subcutaneous Injectable 250 MCG/0.5ML	01/25/2022	12.40	203.20	03/16/2021	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2022	44087000407	Serostim Subcutaneous Solution Reconstituted 4 MG, 7 vials	07/06/2022	176.68	3119.48	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2022	44087000507	Serostim Subcutaneous Solution Reconstituted 5 MG, 7 vials	07/06/2022	220.85	3899.35	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2022	44087000607	Serostim Subcutaneous Solution Reconstituted 6 MG, 7 vials	07/06/2022	265.02	4679.22	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2022	67979051143	AVEED, 750 mg/3mL (250mg/1mL) solution, single use vial	04/01/2022	72.05	1557.60	05/08/2027	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2022	67979051143	Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial	11/21/2022	76.32	1633.92	05/08/2027	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 1/19/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244001002	Edex®, Alprostadil For Inj Kit 10 MCG, 2	01/01/2022	8.10	151.76	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244001006	Edex®, Alprostadil For Inj Kit 10 MCG, 6	01/01/2022	24.32	455.34	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244002002	Edex®, Alprostadil For Inj Kit 20 MCG, 2	01/01/2022	10.47	196.06	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244002006	Edex®, Alprostadil For Inj Kit 20 MCG, 6	01/01/2022	31.41	588.14	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244004002	Edex®, Alprostadil For Inj Kit 40 MCG, 2	01/01/2022	14.30	267.73	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244004006	Edex®, Alprostadil For Inj Kit 40 MCG, 6	01/01/2022	42.89	803.15	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	63481002509	FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9	01/01/2022	87.08	1062.41	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	63481068706	LIDODERM®, Lidocaine Patch 5%, 30	01/01/2022	59.31	723.57	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	63481062970	PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100	01/01/2022	254.82	3108.79	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	63481062770	PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100	01/01/2022	128.88	1572.36	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	63481062370	PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100	01/01/2022	180.38	2200.64	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	63481062385	PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500	01/01/2022	879.21	10726.38	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	63481062870	PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100	01/01/2022	194.88	2377.50	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2022	67979000201	SUPPRELIN LA, 50 mg implant, ea	04/01/2022	2110.37	45179.19	06/16/2026	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244010010	THEO-24®, Theophylline Cap ER 24HR 100 MG, 100	01/01/2022	23.89	291.49	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244020010	THEO-24®, Theophylline Cap ER 24HR 200 MG, 100	01/01/2022	35.51	433.21	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244030010	THEO-24®, Theophylline Cap ER 24HR 300 MG, 100	01/01/2022	43.64	532.45	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2022	52244040010	THEO-24®, Theophylline Cap ER 24HR 400 MG, 100	01/01/2022	61.41	749.23	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2022	67979000101	VALSTAR, 40 mg/1ml solution, 4x5mL	04/01/2022	356.33	7703.43	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2022	67979000101	Valstar, 40 mg/1ml solution, 4x5mL	10/01/2022	373.62	8077.05	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/19/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2022	66887000301	XIAFLEX, 0.9mg powder for solution, single use vial	04/01/2022	212.08	5650.09	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2022	66887000301	Xiaflex, 0.9mg powder for solution, single use vial	10/01/2022	220.35	5870.44	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000405	Esperion	03/31/2022	72426011803	Nexletol 30 Tab 180 mg/1 Tablet Film Coated	01/01/2022	34.63	384.43	12/03/2025	Single Source Drug	149200	None	Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000405	Esperion	03/31/2022	72426081803	Nexlizet 30 Tab 180 mg/1, 10 mg/1 Tablet Film Coated	01/01/2022	34.63	384.43	03/14/2036	Single Source Drug	156754	None	Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000104	EUSA Pharma (US) LLC	12/31/2022	73090042001	SYLVANT 100 mg vial	10/01/2022	57.12	1326.51	09/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000104	EUSA Pharma (US) LLC	12/31/2022	73090042101	SYLVANT 400 mg vial	10/01/2022	228.48	5306.04	09/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000104	EUSA Pharma (US) LLC	06/30/2022	73090042001	Sylvant Intravenous Solution Reconstituted 100 MG	04/01/2022	33.50	1269.39	09/13/2027	Single Source Drug	None	1	None	1	None	1	12/22/2018	Janssen Biotech	115000000	None	Acquisition price is for both NDCs	910.24	883.73	2014	833.00	None	None
Rx0000104	EUSA Pharma (US) LLC	06/30/2022	73090042101	Sylvant Intravenous Solution Reconstituted 400 MG	04/01/2022	134.01	5077.56	09/13/2027	Single Source Drug	None	1	None	1	None	1	12/22/2018	Janssen Biotech	115000000	None	Acquisition price is for both NDCs	3640.96	3534.92	2014	3332.00	None	None
Rx0000455	Evofem Biosciences, Inc.	12/31/2022	69751010012	Phexxi Vaginal Gel 1.8-1-0.4%, 5 GM, Unit-of-Use, Box Qty 12	10/01/2022	44.10	338.10	03/15/2033	Single Source Drug	142452	None	Evofem has experienced unexpectedly high rebate demands from PBMs combined with high demand for patient assistance programs. We had anticipated Phexxi coverage to be improved by the ACA Preventive Services regulations. However most PBMs are not recognizing Phexxi as a preventive contraceptive product.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000063	Ferring Pharmaceuticals	06/30/2022	55566280001	CERVIDIL 10MG VAGINAL INSERT (Dinoprostone 10MG)	04/01/2022	22.85	479.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not apply because Ferring did not acquire the product within the past five years.
Rx0000063	Ferring Pharmaceuticals	06/30/2022	55566750102	Menopur (Menotropins for injection)/75 nits/vial - 5 single dose vials per package	06/01/2022	32.70	1122.15	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not apply because Ferring did not acquire the product within the past five years. NDC 55566750101 is the NDC for the 0.9% Sodium Chloride Injection, USP, 2 mL product included in the Menopur kit. The Sodium Chloride is used for mixing the medicine. NDC 55566750101 does not have a WAC price
Rx0000193	Forte Bio-Pharma, LLC	03/31/2022	72245019310	NALOCET 2.5MG/300MG 100CT TABLETS	01/01/2022	132.19	2776.04	None	Non-innovator Multiple Source Drug	4200	None	Forte Bio considers many factors in the pricing of our products including but not limited to constant competition in the marketplace requires frequent reassements of pricing to ensure consistency with current market, market share has a determining factor on our pricing as we determine our pricing structure to ensure our place in the market, patient population contributes to each pricing decision as this helps determine the profitability of the product and the cost to market our products is continuously rising as we need more resources to properly market the products.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2022	63323061603	Amiodarone HCl Intravenous Solution 150 MG/3ML Package Size 25	12/09/2022	5.25	43.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2022	63323051610	Dexamethasone Sodium Phosphate Inj 100mg 10mL MDV 10 10ML Vials	01/07/2022	12.30	141.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2022	63323050601	Dexamethasone Sodium Phosphate Inj 10mg 1mL PF SDV 1 25ML Vial	01/07/2022	14.75	171.25	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2022	63323016530	Dexamethasone Sodium Phosphate Injection Solution 120 MG/30ML Package Size 1	12/09/2022	3.53	40.71	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2022	76045010610	Dexamethasone Sodium Phosphate Injection Solution 4 MG/ML Package Size 24	11/23/2022	31.86	69.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2022	63323017302	Gentamicin Inj 20mg 2mL PF MDV 2 25ML Vials	01/07/2022	10.25	117.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	09/30/2022	63323017394	Gentamicin Sulfate Injection Solution 10 MG/ML	07/01/2022	3.75	49.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2022	63323085110	HYDROmorphone HCl PF Injection Solution 10 MG/ML Package Size 10	12/09/2022	7.80	47.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2022	76045000120	Midazolam HCl (PF) Injection Solution 2 MG/2ML Package Size 24	11/23/2022	18.00	66.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2022	63323001230	Oxytocin Inj 300USP 30mL MDV 1 Vial	01/07/2022	37.50	432.50	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2022	63323018620	Sodium Chloride (PF) Injection Solution 0.9 % Package Size 25	12/09/2022	6.00	45.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2022	49230064551	Velphoro 90 Count Per Bottle of 500 MG Oral Tablets Chewable	01/07/2022	57.74	1501.25	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2022	63323048257	Xylocaine (Lidocaine HCl) Inj w EPI 500mg 50mL MDV 25pk Single Vial	01/07/2022	20.50	236.25	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000100	Fresenius Medical Care	09/30/2022	49230064551	VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE	09/01/2022	30.03	1531.28	05/26/2035	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code ? 6250 et seq. (?PRA?) as the material contains and constitutes FUSA?s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care is the authorized distributor for Velphoro. Fresenius Medical Care did not acquire Velphoro in the prior five year period.
Rx0000437	Genus Lifesciences Inc.	03/31/2022	64950034245	Hydrocodone with Homatropine solution, 5mL UD, pack of 40	03/01/2022	84.85	390.00	None	Innovator Multiple Source Drug	600	None	Increase in materials, labor and overhead costs	None	Continual evaluation of process improvements	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000406	Glaukos Corporation	03/31/2022	25357002503	Riboflavin 5’-phosphate in 20% dextran ophthalmic solution and riboflavin 5’-phosphate ophthalmic solution, 1.56 mg/mL Photrexa Viscous and 1.46 mg/mL Photrexa, single-use foil pouch, for topical administration	01/01/2022	305.00	3435.00	None	Single Source Drug	None	1	In making the decision to increase the price of Photrexa, Glaukos considered the value in cost savings when it comes to direct medical costs as well as the improved quality of life for keratoconus patients, as compared to corneal transplantation. According to a study published in the Journal of Medical Economics in 2020, corneal cross-linking with Photrexa was found to be cost-effective within 2 years and cost-saving within 4.5 years. We also considered the value it provides to patients in terms of its durability and safety profile, and our significant investment in ongoing research and development, reimbursement and patient support programs, noting that approximately 30-35% of our revenue goes to R&D costs.	None	No change or improvement in the drug product necessitated the price increase.	None	11/21/2019	Avedro, Inc.	437751000	None	Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction.	2850.00	2850.00	2016	595.00	None	None
Rx0000029	GlaxoSmithKline	09/30/2022	49401008801	BENLYSTA; 200 mg/mL; 1 mL in 1 PREFILLED AUTO-INJECTOR (49401-0088-01)	07/01/2022	20.99	1070.54	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	09/30/2022	49401008842	BENLYSTA; 200 mg/mL; 1 mL in 1 PREFILLED GLASS SYRINGE (49401-0088-42)	07/01/2022	20.99	1070.54	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	09/30/2022	49401008835	BENLYSTA; 200 mg/mL; 4 PREFILLED AUTO-INJECTOR in 1 CARTON (49401-0088-35) > 1 mL in 1 PREFILLED AUTO-INJECTOR (49401-0088-01)	07/01/2022	83.96	4282.17	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	09/30/2022	49401008847	BENLYSTA; 200 mg/mL; 4 PREFILLED GLASS SYRINGE in 1 CARTON (49401-0088-47) > 1 mL in 1 PREFILLED GLASS SYRINGE (49401-0088-42)	07/01/2022	83.96	4282.17	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2022	58160097602	BEXSERO 0.5ML Pre-filled Syringe; Dosage form: Injection; 1 Pack	01/01/2022	9.55	200.55	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This product was acquired by GSK in 2015 which is outside of the 5 year reporting period. Therefore, the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2022	58160097620	BEXSERO 0.5ML Pre-filled Syringe; Dosage form: Injection; 10 Pack	01/01/2022	95.50	2005.45	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This product was acquired by GSK in 2015 which is outside of the 5 year reporting period. Therefore, the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2022	58160081912	SHINGRIX 0.5mL Vial; Dosage form: Injection; 1 Pack	01/01/2022	9.56	171.57	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2022	58160082311	SHINGRIX 0.5mL Vial; Dosage form: Injection; 10 Pack	01/01/2022	95.59	1715.68	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2022	69656010330	ZEJULA 100 mg 30 CAPSULE in 1 BOTTLE	01/01/2022	533.53	8155.33	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	01/22/2019	TESARO, INC	None	1	None	6584.00	None	2018	6584.00	None	Note on Acquisition Fields ACQUIRED_FROM_COMPANY: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself ACQUISITION_PRICE: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself WAC_YEAR_PRIOR_TO_ACQ: Zejula did not have a WAC one year prior to acquisition as it was not yet approved at that time
Rx0000123	Greenwich Biosciences	03/31/2022	70127010010	Epidiolex 100mg/mL bottle	01/10/2022	120.00	1540.00	03/01/2041	Single Source Drug	None	1	"Greenwich Biosciences, Inc. manufactures Specialty Pharmacy drugs for rare diseases that require a higher level of administration and effort to support patients. Product prices are determined by conducting extensive market research with Healthcare Providers (HCPs) to assess their perceptions of the clinical value delivered by our products. Greenwich also evaluates relevant market analogues to support a price increase. Greenwich engages its Pricing Committee to make price increase decisions. In doing so, the Pricing Committee balances capturing the product’s value with the priority of ensuring patient access. Specifically, the Pricing Committee considers the following factors in determining whether a price increase is warranted: • Clinical value; • HCP and Payer perceptions of a product’s clinical value; • Patient access and affordability, in order to ensure our products are broadly available to HCPs and patients; • Research and Development costs associated with production of the drug; • Historic WAC price; • Greenwich's fiduciary responsibility to its shareholders."	None	None	1	None	None	None	None	None	None	None	None	None	None	"The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 26, 2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Greenwich Biosciences, Inc. respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The drug was not was acquired from another manufacturer within the last five years."
Rx0000298	H2-Pharma LLC	12/31/2022	61269041020	Etopophos (etoposide phosphate), powder, 100 mg, single-dose vial	10/31/2022	15.35	170.35	None	Single Source Drug	18000	None	Inflation	None	Price on cold packs increased	None	03/01/2020	Bristol-Meyers Squibb	None	1	None	140.94	140.94	1996	99.31	None	None
Rx0000164	Harmony Biosciences, LLC	03/31/2022	72028017803	Wakix Oral Tablet 17.8 MG, 30 each	01/03/2022	324.05	6804.95	09/26/2029	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000164	Harmony Biosciences, LLC	03/31/2022	72028004503	Wakix Oral Tablet 4.45 MG, 30 each	01/03/2022	162.02	3402.47	09/26/2029	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000144	Helsinn Therapeutics, Inc	09/30/2022	69639012001	VALCHLOR 0.016% Gel 60mg Tube	07/01/2022	341.23	5215.92	07/08/2029	Single Source Drug	4229	None	The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000178	Hikma Pharmaceuticals USA Inc	06/30/2022	00143978710	Enalaprilat Injection 1.25mg/mL, 10 vials	06/01/2022	4.78	53.09	None	Non-innovator Multiple Source Drug	None	1	Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	06/30/2022	00143978610	Enalaprilat Injection 2.5mg/2mL, 10 vials	06/01/2022	8.54	94.82	None	Non-innovator Multiple Source Drug	None	1	Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641047721	PHENobarbital Sodium Injection Solution 130 MG/ML, 1 vial	07/05/2022	6.16	68.40	None	Non-innovator Multiple Source Drug	None	1	Increased shipping and distribution costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641047725	PHENobarbital Sodium Injection Solution 130 MG/ML, 25 vials	07/05/2022	154.04	1709.95	None	Non-innovator Multiple Source Drug	None	1	Increased shipping and distribution costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641047625	PHENobarbital Sodium Injection Solution 65 MG/ML	07/05/2022	59.35	658.85	None	Non-innovator Multiple Source Drug	None	1	Increased shipping and distribution costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641620825	Promethazine HCl Injection Solution 25 MG/ML	07/01/2022	19.98	43.64	None	Non-innovator Multiple Source Drug	None	1	Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145	Horizon Therapeutics USA, Inc.	09/30/2022	75987008010	Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial	07/29/2022	624.97	26665.22	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for Krystexxa is not publicly available.
Rx0000160	Incyte Corporation	09/30/2022	50881001060	Jakafi Oral Tablet 10 mg 60 Pack	07/01/2022	311.54	16200.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	09/30/2022	50881001560	Jakafi Oral Tablet 15 mg 60 Pack	07/01/2022	311.54	16200.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	09/30/2022	50881002060	Jakafi Oral Tablet 20 mg 60 Pack	07/01/2022	311.54	16200.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	09/30/2022	50881002560	Jakafi Oral Tablet 25 mg 60 Pack	07/01/2022	311.54	16200.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	09/30/2022	50881000560	Jakafi Oral Tablet 5 mg 60 Pack	07/01/2022	311.54	16200.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	06/30/2022	50742051330	Nitro-Dur Patch 0.1mg/hr 30 ct	04/11/2022	182.26	702.99	None	Single Source Drug	520	None	Increased API, overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	06/30/2022	50742051430	Nitro-Dur Patch 0.2mg/hr 30 ct	04/11/2022	196.09	756.35	None	Single Source Drug	398	None	Increased API, overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	06/30/2022	50742051530	Nitro-Dur Patch 0.3mg/hr 30 ct	04/11/2022	412.15	1589.73	None	Single Source Drug	5100	None	Increased API, overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	06/30/2022	50742051630	Nitro-Dur Patch 0.4mg/hr 30 ct	04/11/2022	219.81	847.85	None	Single Source Drug	284	None	Increased API, overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	06/30/2022	50742051730	Nitro-Dur Patch 0.6mg/hr 30 ct	04/11/2022	238.40	919.53	None	Single Source Drug	291	None	Increased API, overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	06/30/2022	50742051830	Nitro-Dur Patch 0.8mg/hr 30 ct	04/11/2022	446.99	1724.12	None	Single Source Drug	1908	None	Increased API, overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000287	Insmed Incorporated	03/31/2022	71558059028	AMIKACIN LIPOSOME INHALATION SUSPENSION EQ 590MG BASE/8.4ML (28 Vials)	01/01/2022	990.53	13372.21	05/15/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Product developed in-house
Rx0000266	Intercept Pharmaceuticals, Inc.	03/31/2022	69516001030	Ocaliva (obeticholic acid) tablets 10mg 30ct	01/20/2022	448.18	8044.51	05/27/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000266	Intercept Pharmaceuticals, Inc.	03/31/2022	69516000530	Ocaliva (obeticholic acid) tablets 5mg 30ct	01/20/2022	448.18	8044.51	05/27/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054104005	Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml.	01/01/2022	502.00	5629.00	03/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054004301	Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml.	01/01/2022	111.00	2583.00	10/15/2036	Single Source Drug	None	1	None	1	None	1	04/03/2017	Merrimack Pharmaceuticals	None	1	For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf	1652.40	None	2015	1620.00	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054112004	Drug product name: Somatuline Depot - New NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml.	01/01/2022	412.00	9562.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This NDC was launched on September 1, 2019 and will replace NDC 15054112003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054106004	Drug product name: Somatuline Depot - New NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml.	01/01/2022	262.00	6088.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This NDC was launched on September 1, 2019 and will replace NDC 15054106003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054109004	Drug product name: Somatuline Depot - New NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml.	01/01/2022	349.00	8108.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This NDC was launched on September 1, 2019 and will replace NDC 15054109003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054112003	Drug product name: Somatuline Depot - Old NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml.	01/01/2022	412.00	9562.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054109003	Drug product name: Somatuline Depot - Old NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml.	01/01/2022	349.00	8108.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2022	15054106003	Drug product name: Somatuline Depot - Old NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml.	01/01/2022	262.00	6088.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000191	Jaguar Health	12/31/2022	70564080260	Mytesi Oral Tablet Delayed Release 125 MG 60 Tabs	12/01/2022	102.25	2374.55	None	Single Source Drug	1	None	Napo Pharmaceuticals has made the decision to increase the WAC price of Mytesi® by 4.5% effective December 1st, 2022. This price change is due to increases in the cost of business operations related to Mytesi that are consistent with inflation over the past 12 months. The last Mytesi price increase was 12 months ago.	None	Napo Pharmaceuticals has made the decision to increase the WAC price of Mytesi® by 4.5% effective December 1st, 2022. This price change is due to increases in the cost of business operations related to Mytesi that are consistent with inflation over the past 12 months. The last Mytesi price increase was 12 months ago.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000248	Janssen Biotech, Inc.	09/30/2022	57894050205	DARZALEX™ (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial	09/15/2022	26.39	640.19	09/25/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on Janssenpatents.com as of October 4, 2022.
Rx0000248	Janssen Biotech, Inc.	09/30/2022	57894050220	DARZALEX™ (daratumumab)Strength:400 mg 20 mL Package Size:1 Form:1 single vial	09/15/2022	105.57	2560.76	09/25/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on Janssenpatents.com as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458056201	INVEGA® SUSTENNA® Strength:117 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	46.48	1595.84	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458056301	INVEGA® SUSTENNA® Strength:156 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	61.98	2127.87	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458056401	INVEGA® SUSTENNA® Strength:234 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	92.96	3191.73	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458056001	INVEGA® SUSTENNA® Strength:39 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	15.49	531.92	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458056101	INVEGA® SUSTENNA® Strength:78 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	30.99	1063.88	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458060601	INVEGA® TRINZA® Strength:273 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	92.96	3191.63	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458060701	INVEGA® TRINZA® Strength:410 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	139.44	4787.52	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458060801	INVEGA® TRINZA® Strength:546 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	185.93	6383.61	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	09/30/2022	50458060901	INVEGA® TRINZA® Strength:819 mg Package Size:1 Form:Disposable Syringe/Dose Pack	09/15/2022	278.89	9575.20	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676003056	BALVERSA® (erdafitinib) Strength:3 MG Package Size:56 Form:Tablet	09/15/2022	750.48	18203.48	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676003084	BALVERSA® (erdafitinib) Strength:3 MG Package Size:84 Form:Tablet	09/15/2022	1125.72	27305.21	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676004028	BALVERSA® (erdafitinib) Strength:4 MG Package Size:28 Form:Tablet	09/15/2022	500.32	12135.65	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676004056	BALVERSA® (erdafitinib) Strength:4 MG Package Size:56 Form:Tablet	09/15/2022	1000.64	24271.31	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676005028	BALVERSA® (erdafitinib) Strength:5 MG Package Size:28 Form:Tablet	09/15/2022	625.40	15169.57	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676057530	PREZCOBIX™ (darunavir 800mg, cobicistat 150mg) Strength:800 MG/150 MG Package Size:30 Form:Tablet	09/15/2022	66.81	2293.94	10/06/2032	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676056401	PREZISTA® Strength:150 MG Package Size:240 Form:Tablet	09/15/2022	58.46	2006.98	06/26/2027	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676056201	PREZISTA® Strength:600 MG Package Size:60 Form:Tablet	09/15/2022	58.46	2006.98	06/26/2027	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676056301	PREZISTA® Strength:75 MG Package Size:480 Form:Tablet	09/15/2022	58.46	2006.98	06/26/2027	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676056630	PREZISTA® Strength:800 MG Package Size:30 Form:Tablet	09/15/2022	58.46	2006.98	06/26/2027	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000250	Janssen Products, LP	09/30/2022	59676056501	PREZISTA® ORAL SUSPENSION Strength:100MG/mL Package Size:200mL Form:Oral Suspension	09/15/2022	32.47	1114.91	06/26/2027	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000008	Jazz Pharmaceuticals, Inc.	03/31/2022	68727010001	Xyrem 500 MG/ML Oral Solution 180 ml	01/10/2022	465.52	6010.00	09/15/2033	Single Source Drug	None	1	"Jazz Pharmaceuticals manufactures Specialty Pharmacy drugs for rare diseases that require a higher level of administration and effort to support patients. Product prices are determined by conducting extensive market research with Healthcare Providers (HCPs) to assess their perceptions of the clinical value delivered by our products. Jazz also evaluates relevant market analogues to support a price increase. Jazz engages its Pricing Committee to make price increase decisions. In doing so, the Pricing Committee balances capturing the product’s value with the priority of ensuring patient access. Specifically, the Pricing Committee considers the following factors in determining whether a price increase is warranted: • Clinical value; • HCP and Payer perceptions of a product’s clinical value; • Patient access and affordability, in order to ensure our products are broadly available to HCPs and patients; • Research and Development costs associated with production of the drug; • Historic WAC price; • Jazz’s fiduciary responsibility to its shareholders."	None	None	1	None	None	None	None	None	None	None	None	None	None	"The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 26, 2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Columns N-U are intentionally left blank as this drug was not was acquired from another manufacturer within the last five years. "
Rx0000457	Kamada Inc.	09/30/2022	70257053251	CytoGam® [Cytomegalovirus Immune Globulin (Human)] 50 mL Single-dose vial (50mg/ mL) 2.5g	08/01/2022	143.58	1756.85	None	Single Source Drug	None	1	None	1	None	1	11/21/2021	Saol Therapeutics Inc.	None	1	Total acquisition costs for 4 hyperimmune products	1481.42	1412.22	1998	0.01	None	Unknown intro WAC price
Rx0000457	Kamada Inc.	09/30/2022	70257012651	VARIZIG® [Varicella Zoster Immune Globulin (Human)] Sterile Solution =125 IU/vial	08/01/2022	178.37	2182.57	None	Single Source Drug	None	1	None	1	None	1	11/21/2021	Saol Therapeutics Inc.	None	1	Total acquisition costs for 4 hyperimmune products	1892.54	1804.14	2012	682.50	None	Lyophilized product initially, now liquid
Rx0000264	Kedrion Biopharma Inc.	09/30/2022	76125090020	Gammaked™ 200 ml 1 VIAL in 1 CARTON	07/01/2022	152.80	3490.80	12/31/2023	Single Source Drug	84129	None	rising cost of plasma collection and manufacturing	None	na	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	03/31/2022	76125090010	Gammaked™ 10 g protein 100 mL	01/01/2022	78.00	1669.00	12/31/2023	Single Source Drug	66461	None	Rising cost of plasma collection and and increased cost of manufacturing	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	09/30/2022	76125090010	Gammaked™ 100 ml 1 VIAL in 1 CARTON	07/01/2022	76.40	1745.40	12/31/2023	Single Source Drug	66461	None	rising cost of plasma collection and manufacturing	None	na	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	03/31/2022	76125090020	Gammaked™ 20 g protein 200 mL	01/01/2022	156.00	3338.00	12/31/2023	Single Source Drug	84129	None	Rising cost of plasma collection and and increased cost of manufacturing	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	03/31/2022	76125090050	Gammaked™ 5 g protein 50 mL	01/01/2022	39.00	834.50	12/31/2023	Single Source Drug	29199	None	Rising cost of plasma collection and and increased cost of manufacturing	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	09/30/2022	76125090050	Gammaked™ 50 ml 1 VIAL in 1 CARTON	07/01/2022	38.20	872.70	12/31/2023	Single Source Drug	29199	None	rising cost of plasma collection and manufacturing	None	na	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000083	Laboratoire HRA Pharma	03/31/2022	76336008060	Lysodren 500 mg tablets 100 count bottles	03/01/2022	152.01	1165.40	None	Single Source Drug	None	1	None	1	None	1	03/15/2018	BMS	None	1	Trade secret of privately held company. This information is privy only to a few select executives.	479.95	479.95	1970	99.95	None	Column 22 is a best estimate. Pricing software does not report that far back to my knowledge.
Rx0000083	Laboratoire HRA Pharma	03/31/2022	76336045518	Metopirone 250 mg capsules 18 count bottles	03/01/2022	144.93	724.65	None	Single Source Drug	None	1	None	1	None	1	03/01/2011	Novartis	None	1	Trade secret of privately held company. Only a select few executives know the purchase price for this drug.	289.15	289.15	1961	99.95	None	Column 22 is a best estimate. Pricing software does not report that far back to my knowledge.
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2022	11994001116	DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS	01/01/2022	270.30	4775.36	05/04/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2022	11994001104	DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS	01/01/2022	90.10	1216.37	05/04/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000413	Leadiant Biosciences, Inc.	03/31/2022	54482005401	Matulane (Procarbazine Hydrochloride) 50mg Capsules (100 p/bottle)	01/01/2022	1561.19	11969.11	None	Single Source Drug	None	1	Our pricing has been adjusted substantially in consideration of increased manufacturing and supply costs, increased regulatory maintenance costs, and decreasing volumes that make it incrementally onerous for Leadiant to keep Matulane in the market and available to patients.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	We take decisions related to the pricing of our medicines very seriously. Given the complexities of manufacturing products for extremely small patient populations, and the difficulties of maintaining their availability to patients over time, Leadiant strives to find the right balance between ensuring that patients have access to the medicines they need while investing in new therapies for new groups of underserved populations. The costs to produce rare disease products typically increases over time, unlike most other industries. At the same time, our research and development costs are offset by revenues from our approved products.
Rx0000025	Lundbeck LLC	03/31/2022	67386082019	Northera 100mg. 90 Capsules	01/03/2022	153.26	3218.39	None	Single Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2022	67386082019	Northera 100mg. 90 Capsules	07/01/2022	144.83	3363.22	02/18/2021	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386082119	Northera 200mg. 90 Capsules	01/03/2022	306.51	6436.76	None	Single Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2022	67386082119	Northera 200mg. 90 Capsules	07/01/2022	289.65	6726.41	02/18/2021	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386082219	Northera 300mg. 90 Capsules	01/03/2022	459.77	9655.16	None	Single Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2022	67386082219	Northera 300mg. 90 Capsules	07/01/2022	434.48	10089.64	02/18/2021	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386031401	Onfi 10mg. 100 Tablets	01/03/2022	120.61	2532.74	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386031501	Onfi 20mg. 100 Tablets	01/03/2022	241.21	5065.42	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386031321	Onfi Oral Suspension 2.5mg/mL 120mL Bottle	01/03/2022	63.37	1330.72	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386011101	Sabril 500mg. 100 Tablets	01/03/2022	1051.19	18571.01	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2022	67386011101	Sabril 500mg. 100 Tablets	07/01/2022	649.99	19221.00	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386021165	Sabril 500mg. 50 Packets 500mg. each	01/03/2022	525.60	9285.52	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2022	67386021165	Sabril 500mg. 50 Packets 500mg. each	07/01/2022	324.99	9610.51	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386042101	Xenazine 12.5mg. 112 Tablets	01/03/2022	845.27	17750.67	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2022	67386042101	Xenazine 12.5mg. 112 Tablets	07/01/2022	798.78	18549.45	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2022	67386042201	Xenazine 25.0mg. 112 Tablets	01/03/2022	1690.54	35501.35	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2022	67386042201	Xenazine 25.0mg. 112 Tablets	07/01/2022	1597.56	37098.91	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000297	MannKind Corporation	09/30/2022	47918089190	Afrezza 12 Unit Inhalation Powder Metered 1 Carton	07/01/2022	83.50	1276.36	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2022	47918087490	Afrezza 4 Unit Inhalation Powder Metered 1 Carton	07/01/2022	27.83	425.44	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2022	47918088018	Afrezza 4 Unit; 8 Unit Inhalation Powder Metered 1 Carton	07/01/2022	83.50	1276.36	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2022	47918090218	Afrezza 4 Unit; 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton	07/01/2022	111.33	1701.82	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2022	47918087890	Afrezza 8 Unit Inhalation Powder Metered 1 Carton	07/01/2022	55.67	850.91	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2022	47918089818	Afrezza 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton	07/01/2022	139.17	2127.27	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000072	Mayne Pharma Inc	09/30/2022	51862051260	Calcipotriene 0.005% 60g Foam	09/15/2022	153.02	918.12	05/07/2028	Non-innovator Multiple Source Drug	2270	None	Annual WAC Increase	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000072	Mayne Pharma Inc	09/30/2022	51862029550	Fabior 0.1% 50g Foam	09/15/2022	123.68	742.10	02/24/2030	Innovator Multiple Source Drug	47995	None	Annual WAC Increase	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000072	Mayne Pharma Inc	12/31/2022	50261011008	Imvexxy Maintenance Pack Vaginal Insert 10 MCG 8pack	10/01/2022	9.29	215.64	02/02/2034	Single Source Drug	None	1	annual price increase	None	None	None	12/30/2022	THERAPEUTICS MD	153100000	None	For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments.	215.64	196.52	2018	180.00	None	None
Rx0000072	Mayne Pharma Inc	12/31/2022	50261010408	Imvexxy Maintenance Pack Vaginal Insert 4 MCG 8pack	10/01/2022	9.29	215.64	02/02/2034	Single Source Drug	None	1	annual price increase	None	None	None	12/30/2022	THERAPEUTICS MD	153100000	None	For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments.	215.64	196.52	2018	180.00	None	None
Rx0000072	Mayne Pharma Inc	12/31/2022	50261011018	Imvexxy Starter Pack Vaginal Insert 10 MCG 18pack	10/01/2022	20.89	485.18	02/02/2034	Single Source Drug	None	1	annual price increase	None	None	None	12/30/2022	THERAPEUTICS MD	153100000	None	For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments.	485.18	442.18	2018	405.00	None	None
Rx0000072	Mayne Pharma Inc	12/31/2022	50261010418	Imvexxy Starter Pack Vaginal Insert 4 MCG 18pack	10/01/2022	20.89	485.18	02/02/2034	Single Source Drug	None	1	annual price increase	None	None	None	12/30/2022	THERAPEUTICS MD	153100000	None	For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments.	485.18	442.18	2018	405.00	None	None
Rx0000072	Mayne Pharma Inc	09/30/2022	51862037660	Sorilux 0.005% 60g Foam	09/15/2022	177.30	1063.82	05/07/2028	Innovator Multiple Source Drug	9171	None	Annual WAC Increase	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000072	Mayne Pharma Inc	09/30/2022	68308068550	Tazarotene 0.1% 50g Foam	09/15/2022	106.74	640.46	02/24/2030	Non-innovator Multiple Source Drug	10975	None	Annual WAC Increase	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000382	Melinta Therapeutics, LLC	03/31/2022	70842016010	MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (1mg dose)	02/15/2022	205.00	2276.00	05/12/2031	Single Source Drug	None	1	Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors. Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary.	None	None - see cost increase factors statement.	None	01/05/2018	The Medicines Company	None	1	None	1544.13	1544.13	2015	1470.60	None	None
Rx0000138	Merck Sharp & Dohme LLC	09/30/2022	00006412102	GARDASIL 9 0.5 mL Syringes 10	08/12/2022	151.71	2680.23	12/10/2028	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: • capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. • investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET).
Rx0000138	Merck Sharp & Dohme LLC	09/30/2022	00006411903	GARDASIL 9 0.5 mL Vials 10	08/12/2022	151.71	2680.23	12/10/2028	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: • capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. • investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET).
Rx0000138	Merck Sharp & Dohme LLC	09/30/2022	00006417100	PROQUAD 0.5 mL Vials 10	08/12/2022	123.51	2593.67	None	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: • capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. • investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET).
Rx0000138	Merck Sharp & Dohme LLC	09/30/2022	00006482700	VARIVAX 0.5 mL Vials 10	08/12/2022	90.14	1592.41	None	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: • capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. • investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET).
Rx0000051	MILLICENT U.S., INC.	03/31/2022	72495020105	FEMRING 0.05MG/DAY (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGE	01/01/2022	54.66	636.11	None	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	485.37	443.67	2003	76.50	None	None
Rx0000051	MILLICENT U.S., INC.	03/31/2022	72495020210	FEMRING 0.10mFEMRING 0.10MG/DAY (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGEG	01/01/2022	58.25	677.86	None	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	517.23	472.79	2003	81.50	None	None
Rx0000051	MILLICENT U.S., INC.	03/31/2022	72495040128	INTRAROSA 6.5mg/DAY (PRASTERONE INSERTS)	01/01/2022	14.02	240.12	03/19/2031	Single Source Drug	None	1	None	1	None	1	04/26/2020	AMAG	None	1	None	212.30	202.00	2017	175.00	None	None
Rx0000046	Mylan Specialty LP	09/30/2022	49502080693	Yupelri (revefenacin) inhalation solution 175mcg/3mL, 30 vials	07/05/2022	56.80	1216.01	08/25/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165002030	ADZENYS XR-ODT 12.5MG, 30 CT Tablets	10/01/2022	21.78	457.38	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165002530	ADZENYS XR-ODT 15.7MG, 30 CT Tablets	10/01/2022	21.78	457.38	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165003030	ADZENYS XR-ODT 18.8MG, 30 CT Tablets	10/01/2022	21.78	457.38	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165000530	ADZENYS XR-ODT 3.1MG, 30 CT Tablets	10/01/2022	21.78	457.38	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165001030	ADZENYS XR-ODT 6.3MG, 30 CT Tablets	10/01/2022	21.78	457.38	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165001530	ADZENYS XR-ODT 9.4MG, 30 CT Tablets	10/01/2022	21.78	457.38	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165020030	COTEMPLA XR-ODT 17.3MG, 30 CT Tablets	10/01/2022	22.26	467.46	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165030030	COTEMPLA XR-ODT 25.9MG, 30 CT Tablets	10/01/2022	22.26	467.46	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2022	70165010030	COTEMPLA XR-ODT 8.6MG, 30 CT Tablets	10/01/2022	22.26	467.46	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2022	70370204001	INGREZZA ORAL CAPSULE 40 MG, BOTTLE OF 30 CAPSULES	10/20/2022	603.00	7302.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2022	70370108001	INGREZZA ORAL CAPSULE 80 MG, BOTTLE OF 30 CAPSULES	10/20/2022	662.00	8022.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2022	70370204806	INGREZZA ORAL CAPSULE INITIATION PACK 40 MG (7) AND 80 MG (21), BLISTER PACK OF 28 CAPSULES	10/20/2022	662.00	8022.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000364	NextWave Pharmaceuticals, Inc.	03/31/2022	24478032102	QUILLIVANT XR 300mg in 60mL Powder 1 60mL Bottle 1 Carton	01/03/2022	9.98	338.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000364	NextWave Pharmaceuticals, Inc.	03/31/2022	24478032204	QUILLIVANT XR 600mg in 120mL Powder 1 120mL Bottle 1 Carton	01/03/2022	9.98	338.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000364	NextWave Pharmaceuticals, Inc.	03/31/2022	24478032305	QUILLIVANT XR 900mg in 180mL Powder 1 180mL Bottle 1 Carton	01/03/2022	9.98	338.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000364	NextWave Pharmaceuticals, Inc.	03/31/2022	24478032406	QUILLIVANT XR750mg in 150mL Powder 1 150mL Bottle 1 Carton	01/03/2022	9.98	338.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000418	Nexus Pharmaceuticals, Inc.	09/30/2022	14789090110	Procainamide HCL 100 mg 10mL Vial Pack of 10	09/07/2022	3000.00	6000.00	None	Non-innovator Multiple Source Drug	6790	None	Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions.	None	no change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000418	Nexus Pharmaceuticals, Inc.	09/30/2022	14789090002	Procainamide HCL 500mg 2mL Vial Pack of 10	09/07/2022	3000.00	6000.00	None	Non-innovator Multiple Source Drug	15140	None	Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions.	None	no change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	12/31/2022	59584013801	Candin skin test antigen 1 U/.1mL 1mL vial liquid	10/10/2022	29.00	272.00	None	Single Source Drug	31873	None	When pricing its products, Nielsen takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	12/31/2022	59584014001	Spherusol skin test antigen 12.7 ug/mL 1mL vial liquid	10/10/2022	138.00	1056.00	None	Single Source Drug	1155	None	When pricing its products, Nielsen takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	03/31/2022	70839015030	TEKTURNA 150MG TAB 30/EA	01/01/2022	22.02	266.64	08/19/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	03/31/2022	70839030030	TEKTURNA 300MG TAB 30/EA	01/01/2022	27.78	336.39	08/19/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	03/31/2022	70839031230	TEKTURNA HCT 300/12.5MG TAB 30/EA	01/01/2022	27.78	336.39	07/13/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	03/31/2022	70839032530	TEKTURNA HCT 300/25MG TAB 30/EA	01/01/2022	27.78	336.39	07/13/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000073	Novartis	09/30/2022	00065027510	AZOPT® 1% 10 mL DT	07/27/2022	17.16	360.39	07/02/2017	Innovator Multiple Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00065027515	AZOPT® 1% 15 mL DT	07/27/2022	25.74	540.54	07/02/2017	Innovator Multiple Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078063968	Cosentyx 150mg/ml, pen, 1 Sensoready Pen	01/05/2022	415.05	6344.38	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078063968	Cosentyx 150mg/ml, pen, 1 Sensoready Pen	07/27/2022	126.89	6471.27	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078063941	Cosentyx 150mg/ml, pen, 2 Sensoready Pens	01/05/2022	415.05	6344.38	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078063941	Cosentyx 150mg/ml, pen, 2 Sensoready Pens	07/27/2022	126.89	6471.27	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078063997	Cosentyx 150mg/ml, syringe, 1 Syringe	01/05/2022	415.05	6344.38	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078063997	Cosentyx 150mg/ml, syringe, 1 Syringe	07/27/2022	126.89	6471.27	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078063998	Cosentyx 150mg/ml, syringe, 2 Syringes	01/05/2022	415.05	6344.38	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078063998	Cosentyx 150mg/ml, syringe, 2 Syringes	07/27/2022	126.89	6471.27	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00065924007	DUREZOL® 0.05% 5 mL DT	07/27/2022	10.38	218.00	11/18/2019	Innovator Multiple Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078065967	Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle	01/05/2022	122.41	1871.09	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078065967	Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle	07/27/2022	37.42	1908.51	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078065920	Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle	01/05/2022	40.80	623.69	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078065920	Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle	07/27/2022	12.47	636.16	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078077767	Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle	01/05/2022	122.41	1871.09	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078077767	Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle	07/27/2022	37.42	1908.51	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078077720	Entresto 49/51mg - Tabs, 60 Each Bottle, 1 bottle	01/05/2022	40.80	623.69	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078069667	Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle	01/05/2022	122.41	1871.09	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078069667	Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle	07/27/2022	37.42	1908.51	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078069620	Entresto 97/103mg - Tabs, 60 Each Bottle, 1 bottle	01/05/2022	40.80	623.69	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078077720	ENTRESTO® tablets 49mg/51mg 60s	07/27/2022	12.47	636.16	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078069620	ENTRESTO® tablets 97mg/103mg 60s	07/27/2022	12.47	636.16	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078060715	GILENYA capsules 0.5mg 30s	01/05/2022	454.77	9550.11	12/25/2027	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078060715	GILENYA capsules 0.5mg 30s	07/27/2022	191.00	9741.11	12/25/2027	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078074303	ILEVRO® 0.3% 3 mL	07/27/2022	6.46	329.47	03/31/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078086001	KISQALI 200mg daily dose, 1 blister pack x 21 tablets (21 tablets per carton)	01/05/2022	396.77	6064.92	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078086742	KISQALI 400mg daily dose, 3 blister packs x 14 tablets (42 tablets per carton)	01/05/2022	793.54	12129.88	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078087463	KISQALI 600mg daily dose, 3 blister packs x 21 tablets (63 tablets per carton)	01/05/2022	991.93	15162.35	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078090961	KISQALI FEMARA CO-PACK, Kisqali 1 blister pack, containing 21 tablets 200mg per tablet, Femara 2.5mg 28s	01/05/2022	396.77	6064.92	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078091661	KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 14 tablets (200mg per tablet) (400mg daily	01/05/2022	793.54	12129.88	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078092361	KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 21 tablets (200mg per tablet) (600mg daily dose), Femara 2.5mg 28s	01/05/2022	991.93	15162.35	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078097950	MAYZENT tablets .25mg 28s	01/05/2022	94.01	1974.15	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078097950	MAYZENT tablets .25mg 28s	07/27/2022	39.48	2013.63	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078098615	MAYZENT tablets 2mg 30s	01/05/2022	402.89	8460.63	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078098615	MAYZENT tablets 2mg 30s	07/27/2022	169.21	8629.84	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078066615	Mekinist 0.5 mg 30 tabs per bottle, 1 bottle	01/05/2022	203.63	3905.92	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078066615	Mekinist 0.5 mg 30 tabs per bottle, 1 bottle	07/27/2022	78.12	3984.04	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078066815	Mekinist 2 mg 30 tabs per bottle, 1 bottle	01/05/2022	693.04	13293.83	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078066815	Mekinist 2 mg 30 tabs per bottle, 1 bottle	07/27/2022	265.88	13559.71	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078070184	PIQRAY tablets 200mg 28s	01/05/2022	1224.80	18721.98	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078071502	PIQRAY tablets 250mg 56s	01/05/2022	1224.80	18721.98	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078070802	PIQRAY tablets 300mg 56s	01/05/2022	1224.80	18721.98	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078068415	Promacta 12.5 mg, 30 tabs per bottle, 1 bottle	01/05/2022	394.82	6035.13	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078068415	Promacta 12.5 mg, 30 tabs per bottle, 1 bottle	07/27/2022	120.70	6155.83	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078068515	Promacta 25 mg, 30 tabs per bottle, 1 bottle	01/05/2022	394.82	6035.13	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078068515	Promacta 25 mg, 30 tabs per bottle, 1 bottle	07/27/2022	120.70	6155.83	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078068615	Promacta 50 mg, 30 tabs per bottle, 1 bottle	01/05/2022	714.50	10921.67	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078068615	Promacta 50 mg, 30 tabs per bottle, 1 bottle	07/27/2022	218.43	11140.10	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078068715	Promacta 75 mg, 30 tabs per bottle, 1 bottle	01/05/2022	1071.75	16382.51	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078068715	Promacta 75 mg, 30 tabs per bottle, 1 bottle	07/27/2022	327.65	16710.16	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078097261	PROMACTA powder for oral suspension 12.5mg 30s Kit	01/05/2022	394.82	6035.13	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078097261	PROMACTA powder for oral suspension 12.5mg 30s Kit	07/27/2022	120.70	6155.83	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078069761	PROMACTA® powder for oral suspension 12.5mg 30s Kit	07/27/2022	120.71	6156.16	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078068655	PROMACTA® tablets 50mg 14s	07/27/2022	101.94	5198.71	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078069819	Rydapt 25 mg, 112 tabs per bottle, 1 bottle	01/05/2022	1040.78	19964.05	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078069899	Rydapt 25 mg, 56 tabs per bottle, 1 bottle	01/05/2022	520.39	9982.03	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078068266	Tafinlar 50 mg, 120 tabs per bottle, 1 bottle	01/05/2022	495.30	9500.83	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078068266	Tafinlar 50 mg, 120 tabs per bottle, 1 bottle	07/27/2022	190.02	9690.85	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078068166	Tafinlar 75 mg, 120 tabs per bottle, 1 bottle	01/05/2022	638.32	12244.20	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	09/30/2022	00078068166	Tafinlar 75 mg, 120 tabs per bottle, 1 bottle	07/27/2022	244.88	12489.08	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2022	00078059287	Tasigna 150mg, 28 capsule per bottle, 4 bottles	01/05/2022	944.77	16690.91	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078059287	Tasigna 150mg, 28 capsule per bottle, 4 bottles	07/27/2022	333.82	17024.73	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078052687	Tasigna 200mg, 28 capsule per bottle, 4 bottles	01/05/2022	944.77	16690.91	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078052687	Tasigna 200mg, 28 capsule per bottle, 4 bottles	07/27/2022	333.82	17024.73	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078095166	Tasigna 50mg, 120 capsule per bottle, 1 bottle	01/05/2022	1012.25	17883.06	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	09/30/2022	00078095166	Tasigna 50mg, 120 capsule per bottle, 1 bottle	07/27/2022	357.66	18240.72	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2022	00078067066	Votrient 200 mg 120 tabs per bottle, 1 bottle	01/05/2022	800.62	15357.34	10/19/2023	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968051408	CombiPatch Transdermal Patch Twice Weekly 0.05-0.14 MG/DAY - 8 each	01/01/2022	11.02	231.49	None	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968052508	CombiPatch Transdermal Patch Twice Weekly 0.05-0.25 MG/DAY - 8 each	01/01/2022	11.02	231.49	None	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968555203	Daytrana Transdermal Patch 10 MG/9HR - 30 each	01/01/2022	20.99	440.97	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968555303	Daytrana Transdermal Patch 15 MG/9HR - 30 each	01/01/2022	20.99	440.97	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968555403	Daytrana Transdermal Patch 20 MG/9HR - 30 each	01/01/2022	20.99	440.97	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968555503	Daytrana Transdermal Patch 30 MG/9HR - 30 each	01/01/2022	20.99	440.97	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968662508	Minivelle Transdermal Patch Twice Weekly 0.025 MG/24HR - 8 each	01/01/2022	10.43	219.13	07/04/2030	Innovator Multiple Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968663708	Minivelle Transdermal Patch Twice Weekly 0.0375 MG/24HR - 8 each	01/01/2022	10.43	219.13	07/04/2030	Innovator Multiple Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968665008	Minivelle Transdermal Patch Twice Weekly 0.05 MG/24HR - 8 each	01/01/2022	10.43	219.13	07/04/2030	Innovator Multiple Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968667508	Minivelle Transdermal Patch Twice Weekly 0.075 MG/24HR - 8 each	01/01/2022	10.43	219.13	07/04/2030	Innovator Multiple Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2022	68968661008	Minivelle Transdermal Patch Twice Weekly 0.1 MG/24HR - 8 each	01/01/2022	10.43	219.13	07/04/2030	Innovator Multiple Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000033	Novo	03/31/2022	00169770521	Norditropin® FlexPro® 10mg/1.5mL	01/06/2022	66.66	1465.40	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2022	00169770821	Norditropin® FlexPro® 15mg/1.5mL	01/06/2022	100.00	2198.10	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2022	00169770321	Norditropin® FlexPro® 30mg/3.0mL	01/06/2022	199.99	4396.20	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2022	00169770421	Norditropin® FlexPro® 5mg/1.5mL	01/06/2022	33.33	732.70	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2022	69102013710	Lamotrigine USP Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets	02/01/2022	32.00	680.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2022	69102030001	Subvenite (lamotrigine USP) Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets	02/01/2022	32.00	680.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000101	Par Pharmaceutical	09/30/2022	42023010501	BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL	09/19/2022	15.01	85.92	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000101	Par Pharmaceutical	09/30/2022	42023011925	TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl	09/19/2022	203.95	1167.61	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000053	Paratek Pharmaceuticals, Inc.	03/31/2022	71715000227	Nuzyra Oral Tablet 150 MG 30 pack	01/01/2022	204.30	7014.41	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2022	71715000227	Nuzyra Oral Tablet 150 MG 30 pack	07/01/2022	210.43	7224.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	03/31/2022	71715000221	Nuzyra Oral Tablet 150 MG 6 pack	01/01/2022	40.86	1402.88	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2022	71715000221	Nuzyra Oral Tablet 150 MG 6 pack	07/01/2022	42.09	1444.95	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000006	Pfizer	03/31/2022	00409592101	AMINOPHYLLINE (aminophylline), 250 mg/10 mL, VIAL (ML), 1	01/01/2022	31.25	343.77	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409592201	AMINOPHYLLINE (aminophylline), 500 mg/20 mL, VIAL (ML), 1	01/01/2022	20.11	221.25	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009722402	ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5	01/01/2022	2862.89	14314.46	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409963005	ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1	01/01/2022	13.92	153.08	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409491134	ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1	01/01/2022	10.42	114.62	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409491034	ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1	01/01/2022	9.10	100.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409163010	ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1	01/01/2022	5.80	63.75	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409963005	Atropine Sulfate Injection Rx, 0.05 mg/mL (0.25 mg/5 mL) Ansyr™ Plastic Syringe, 10	07/01/2022	15.31	168.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409491034	Atropine Sulfate Injection Rx, 0.1 mg/mL (0.5 mg/5 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10	07/01/2022	10.01	110.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409163010	Atropine Sulfate Injection Rx, 0.1 mg/mL (1 mg/10 mL) Ansyr™ Plastic Syringe, 10	07/01/2022	6.38	70.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409491134	Atropine Sulfate Injection Rx, 0.1 mg/mL (1 mg/10 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10	07/01/2022	11.46	126.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409196612	Bacteriostatic 0.9% Sodium Chloride Injection Rx, 10 mL (0.9%) Multiple Dose LifeShield™ Plastic Fliptop Vial, 25	07/01/2022	4.38	48.18	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409397703	Bacteriostatic Water Injection Rx, 30 mL Multiple Dose Plastic Fliptop Vial, 25	07/01/2022	3.73	41.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	60793060110	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1	01/01/2022	137.23	1509.57	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	60793060010	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1	01/01/2022	137.23	1509.57	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	60793060210	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), SYRINGE (ML), 1	01/01/2022	137.23	1509.57	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793060210	Bicillin C-R 900/300® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1" needle) Pediatric, 10	07/01/2022	150.96	1660.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793060110	Bicillin C-R® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1" needle) Pediatric, 10	07/01/2022	150.96	1660.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793060010	Bicillin C-R® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 10	07/01/2022	150.96	1660.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	60793070110	BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1	01/01/2022	172.16	1893.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	60793070210	BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1	01/01/2022	352.78	3880.58	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	60793070010	BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1	01/01/2022	99.40	1093.41	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793070010	Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 1 mL Pre-Filled Syringe (21 gauge x 1" needle) Pediatric, 10	07/01/2022	109.34	1202.75	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793070110	Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 2 mL Pre-Filled Syringe (21 gauge x 1-1/2" needle), 10	07/01/2022	189.37	2083.11	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793070210	Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 4 mL Pre-Filled Syringe (18 gauge x 1-1/2" needle), 10	07/01/2022	388.06	4268.64	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069013501	BOSULIF (bosutinib), 100 mg, TABLET, 1	01/01/2022	905.11	17361.70	04/01/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069019301	BOSULIF (bosutinib), 400 mg, TABLET, 1	01/01/2022	905.11	17361.70	04/01/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069013601	BOSULIF (bosutinib), 500 mg, TABLET, 1	01/01/2022	905.11	17361.70	04/01/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409162301	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10	07/01/2022	4.61	50.67	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409162601	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10	07/01/2022	5.63	61.97	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409162602	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10	07/01/2022	7.93	87.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409492834	CALCIUM CHLORIDE (calcium chloride), 100 mg/mL (10 %), SYRINGE (ML), 1	01/01/2022	9.65	106.15	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409163110	Calcium Chloride Injection Rx, 100 mg/mL (1 g/10 mL) Ansyr™ Plastic Syringe, 10	07/01/2022	7.84	86.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409492834	Calcium Chloride Injection Rx, 100 mg/mL (1 g/10 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10	07/01/2022	10.62	116.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409337301	Corlopam® (fenoldopam mesylate) Injection Rx, 10 mg Single Dose Vial, 1	07/01/2022	41.36	454.95	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409337302	Corlopam® (fenoldopam mesylate) Injection Rx, 20 mg Single Dose Vial, 1	07/01/2022	82.72	909.91	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069153130	DAURISMO (glasdegib maleate), 100 mg, TABLET, 1	01/01/2022	1026.29	19686.10	01/30/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2031 upon the grant of the patent term extension application.
Rx0000006	Pfizer	03/31/2022	00069029860	DAURISMO (glasdegib maleate), 25 mg, TABLET, 1	01/01/2022	1026.29	19686.10	01/30/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2031 upon the grant of the patent term extension application.
Rx0000006	Pfizer	03/31/2022	00409125502	DEMEROL (meperidine HCl/PF), 100 mg/2 mL, AMPUL (ML), 1	01/01/2022	5.51	115.78	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409118130	Demerol™ (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1	07/01/2022	4.06	85.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009027101	DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1	01/01/2022	11.58	127.35	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00009027101	Depo-Estradiol® (estradiol cypionate) Sterile Solution Rx, 5 mg/mL 5 mL Vial, 1	07/01/2022	12.74	140.09	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409177510	DEXTROSE IN WATER (dextrose 25 % in water), 25 %, SYRINGE (ML), 1	01/01/2022	9.60	105.64	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409490234	DEXTROSE IN WATER (dextrose 50 % in water), 50 %, SYRINGE (ML), 1	01/01/2022	9.41	103.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409751716	DEXTROSE IN WATER (dextrose 50 % in water), 50 %, SYRINGE (ML), 1	01/01/2022	9.20	101.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409664802	DEXTROSE IN WATER (dextrose 50 % in water), 50 %, VIAL (ML), 1	01/01/2022	7.76	85.39	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409751716	Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) Ansyr™ II Plastic Syringe (side/side), 10	07/01/2022	10.12	111.34	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409490234	Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) LifeShield™ Abboject™ Glass Syringe (18 G x 1 1/2"), 10	07/01/2022	10.35	113.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409664802	Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) Single Dose Glass Fliptop Vial, 25	07/01/2022	8.54	93.93	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409710067	Dextrose Injection Rx, 100 mL (5%) ADD-Vantage™ Flexible Container, 50	07/01/2022	13.63	149.92	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409177510	Dextrose Injection Rx, 250 mg/mL (2.5 g/10 mL) (25%) Ansyr™ Plastic Syringe, 10	07/01/2022	10.56	116.20	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409710002	Dextrose Injection Rx, 250 mL (5%) ADD-Vantage™ Flexible Container, 24	07/01/2022	8.68	95.45	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409710066	Dextrose Injection Rx, 50 mL (5%) ADD-Vantage™ Flexible Container, 50	07/01/2022	13.46	148.02	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409910420	DOPAMINE HCL (dopamine HCl), 400 mg/10 mL (40 mg/mL), VIAL (ML), 1	01/01/2022	5.41	59.46	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409493301	Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10	07/01/2022	5.76	63.38	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069021702	Fragmin® (dalteparin sodium) Injection Rx, 10,000 IU/1 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	07/01/2022	90.73	998.07	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069022002	Fragmin® (dalteparin sodium) Injection Rx, 12,500 IU/0.5 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	07/01/2022	113.43	1247.68	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069022302	Fragmin® (dalteparin sodium) Injection Rx, 15,000 IU/0.6 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	07/01/2022	136.10	1497.13	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069022802	Fragmin® (dalteparin sodium) Injection Rx, 18,000 IU/0.72 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards test potency, 10	07/01/2022	163.32	1796.55	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069019502	Fragmin® (dalteparin sodium) Injection Rx, 2,500 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	07/01/2022	27.96	307.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069019602	Fragmin® (dalteparin sodium) Injection Rx, 5,000 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	07/01/2022	45.37	499.04	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069020602	Fragmin® (dalteparin sodium) Injection Rx, 7,500 IU/0.3 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	07/01/2022	68.06	748.64	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069023201	Fragmin® (dalteparin sodium) Injection Rx, 95,000 IU/3.8 mL Multidose Vial, 1	07/01/2022	77.99	857.89	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409163910	FUROSEMIDE (furosemide), 10 mg/mL, SYRINGE (ML), 1	01/01/2022	18.54	203.94	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409963104	FUROSEMIDE (furosemide), 10 mg/mL, SYRINGE (ML), 1	01/01/2022	11.12	122.34	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409163910	Furosemide Injection Rx, 10 mg/mL (100 mg/10 mL) Ansyr™ Plastic Syringe, 10	07/01/2022	20.39	224.33	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409963104	Furosemide Injection Rx, 10 mg/mL (40 mg/4 mL) Ansyr™ Plastic Syringe, 10	07/01/2022	12.23	134.57	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409120703	Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25	07/01/2022	7.04	35.21	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409765062	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24	07/01/2022	23.32	256.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409765162	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 50 Units/mL (12,500 Units/250 mL) Flexible Container, 24	07/01/2022	20.17	221.87	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069013703	HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1	01/01/2022	0.77	77.74	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069005801	HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1	01/01/2022	0.84	84.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409272003	HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1	01/01/2022	1.92	194.31	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409272001	HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1	01/01/2022	0.46	46.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409272002	HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1	01/01/2022	0.84	84.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409272101	HEPARIN SODIUM (heparin sodium,porcine), 10,000 unit/mL, VIAL (ML), 1	01/01/2022	0.81	82.30	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409140212	HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL (1 mL), CARTRIDGE (ML), 1	01/01/2022	1.43	144.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069005901	HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1	01/01/2022	2.88	291.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409272301	HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1	01/01/2022	0.50	50.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069005903	HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1	01/01/2022	1.04	105.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409272302	HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML),1	01/01/2022	2.88	291.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409131632	HEPARIN SODIUM (heparin sodium,porcine/PF), 5,000 unit/0.5 mL, CARTRIDGE (ML), 1	01/01/2022	4.98	170.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409765062	HEPARIN SODIUM IN 0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 1	01/01/2022	1.16	233.19	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409765162	HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 12,500 unit/250 mL, INTRAVENOUS SOLUTION, 1	01/01/2022	1.00	201.70	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409765103	HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/500 mL (50 unit/mL), INTRAVENOUS SOLUTION, 1	01/01/2022	17.58	193.33	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409762003	HEPARIN SODIUM-0.9% NACL (heparin sodium,porcine IN 0.9 % sodium chloride/PF), 1,000 unit/500 mL (2 unit/mL), INTRAVENOUS SOLUTION, 1	01/01/2022	0.98	98.91	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409762059	HEPARIN SODIUM-0.9% NACL (heparin sodium,porcine IN 0.9 % sodium chloride/PF), 2,000 unit/1,000 mL (2 unit/mL), INTRAVENOUS SOLUTION, 1	01/01/2022	0.80	80.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409779362	HEPARIN SODIUM-D5W (heparin sodium,porcine/dextrose 5 % in water), 25,000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 1	01/01/2022	2.29	230.99	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409128305	Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (0.5 mg/0.5 mL) iSecure™ Luer Lock Glass Syringe (no needle), 10	07/01/2022	2.85	31.35	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409255201	Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (1 mg/1 mL) Glass Ampul, 10	07/01/2022	2.03	22.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069018821	IBRANCE (palbociclib), 100 mg, CAPSULE, 1	01/01/2022	901.96	13973.80	03/05/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069018921	IBRANCE (palbociclib), 125 mg, CAPSULE, 1	01/01/2022	901.96	13973.80	03/05/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069018721	IBRANCE (palbociclib), 75 mg, CAPSULE, 1	01/01/2022	901.96	13973.80	03/05/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069014501	INLYTA (axitinib), 1 mg, TABLET, 1	01/01/2022	1147.36	17775.76	04/29/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069015111	INLYTA (axitinib), 5 mg, TABLET, 1	01/01/2022	1147.36	17775.76	04/29/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409913705	LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1	01/01/2022	6.99	76.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409490434	LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1	01/01/2022	10.16	111.72	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409913705	Lidocaine Hydrochloride Injection Rx, 1% (10 mg/mL) 50 mg/5 mL Ansyr™ Plastic Syringe, 10	07/01/2022	7.69	84.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409490434	Lidocaine Hydrochloride Injection Rx, 1% (10 mg/mL) 50 mg/5 mL LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10	07/01/2022	11.17	122.89	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409132305	Lidocaine Hydrochloride Injection Rx, 2% (20 mg/mL) 100 mg/5 mL Ansyr™ Plastic Syringe, 10	07/01/2022	3.73	41.04	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409490334	Lidocaine Hydrochloride Injection Rx, 2% (20 mg/mL) 100 mg/5 mL LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10	07/01/2022	3.89	42.82	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069023101	LORBRENA (lorlatinib), 100 mg, TABLET, 1	01/01/2022	973.58	18675.11	03/05/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069022701	LORBRENA (lorlatinib), 25 mg, TABLET, 1	01/01/2022	324.53	6225.05	03/05/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409175410	MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1	01/01/2022	19.01	209.12	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409175410	Magnesium Sulfate Injection Rx, 500 mg/mL (5 g/10 mL) Ansyr™ Plastic Syringe, 10	07/01/2022	20.91	230.03	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409259603	MIDAZOLAM HCL (midazolam HCl), 5 mg/mL, VIAL (ML), 1	01/01/2022	0.44	44.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409464601	PANCURONIUM BROMIDE (pancuronium bromide), 1 mg/mL, VIAL (ML), 1	01/01/2022	6.81	142.93	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	06/30/2022	00069101102	Panzyga (immune globulin intravenous, human - ifas) 1 g/10 mL Vial, 1	04/01/2022	2.84	193.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	06/30/2022	00069131202	Panzyga (immune globulin intravenous, human - ifas) 10 g/100 mL Vial, 1	04/01/2022	28.40	1930.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	06/30/2022	00069110902	Panzyga (immune globulin intravenous, human - ifas) 2.5 g/25 mL Vial, 1	04/01/2022	7.10	482.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	06/30/2022	00069141502	Panzyga (immune globulin intravenous, human - ifas) 20 g/200 mL Vial, 1	04/01/2022	56.80	3860.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	06/30/2022	00069155802	Panzyga (immune globulin intravenous, human - ifas) 30 g/300 mL Vial, 1	04/01/2022	85.20	5790.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	06/30/2022	00069122402	Panzyga (immune globulin intravenous, human - ifas) 5 g/50 mL Vial, 1	04/01/2022	14.20	965.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069101102	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 1 g/10 mL Vial, 1	07/01/2022	2.90	195.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	12/31/2022	00069101102	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 1 g/10 mL Vial, 1	10/01/2022	2.94	198.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069131202	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1	07/01/2022	29.00	1959.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	12/31/2022	00069131202	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1	10/01/2022	29.40	1988.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069110902	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1	07/01/2022	7.25	489.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	12/31/2022	00069110902	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1	10/01/2022	7.35	497.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069141502	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1	07/01/2022	58.00	3918.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	12/31/2022	00069141502	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1	10/01/2022	58.80	3976.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069155802	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1	07/01/2022	87.00	5877.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	12/31/2022	00069155802	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1	10/01/2022	88.20	5965.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00069122402	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1	07/01/2022	14.50	979.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	12/31/2022	00069122402	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1	10/01/2022	14.70	994.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793013010	Penicillin G Procaine Injectable Suspension Rx, 1 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 1	07/01/2022	37.98	417.74	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	60793013110	Penicillin G Procaine Injectable Suspension Rx, 2 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 1	07/01/2022	63.84	702.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00005197105	PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (Diphtheria crm) / PF), 0.5 mL, SYRINGE (ML), 1	01/01/2022	15.02	232.76	11/09/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00005197102	PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (Diphtheria crm)/PF), 0.5 mL, SYRINGE (ML), 1	01/01/2022	145.67	2256.81	11/09/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409553414	Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10	07/01/2022	12.49	137.35	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409491614	Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10	07/01/2022	16.17	177.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409490014	Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10	07/01/2022	16.13	177.39	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409663714	Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10	07/01/2022	11.91	131.01	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409488850	SODIUM CHLORIDE (0.9 % sodium chloride), 0.9 %, VIAL (ML), 1	01/01/2022	6.38	70.15	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409488812	SODIUM CHLORIDE (0.9 % sodium chloride), 0.9 %, VIAL (ML), 1	01/01/2022	4.15	45.65	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409196612	SODIUM CHLORIDE (bacteriostatic sodium chloride), 0.9 %, VIAL (ML), 1	01/01/2022	3.98	43.80	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409114102	SODIUM CHLORIDE (sodium chloride), 4 mEq/mL, VIAL (ML), 1	01/01/2022	0.96	96.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409488812	Sodium Chloride Injection Rx, 0.9% (10 mL) Single Dose LifeShield™ Plastic Fliptop Vial, 25	07/01/2022	4.57	50.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409710167	Sodium Chloride Injection Rx, 0.9% (100 mL) ADD-Vantage™ Flexible Container, 50	07/01/2022	13.80	151.83	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409710102	Sodium Chloride Injection Rx, 0.9% (250 mL) ADD-Vantage™ Flexible Container, 24	07/01/2022	8.73	96.05	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409710166	Sodium Chloride Injection Rx, 0.9% (50 mL) ADD-Vantage™ Flexible Container, 50	07/01/2022	13.98	153.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2022	00409488850	Sodium Chloride Injection Rx, 0.9% (50 mL) Single Dose Plastic Fliptop Vial, 25	07/01/2022	7.02	77.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00409666075	SODIUM CHLORIDE, 2.5 mEq/mL, Vial, 40	01/01/2022	4.93	39.86	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009082501	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, Vial, 1	01/01/2022	2.28	13.69	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009000501	SOLU-CORTEF (hydrocortisone sodium succinate/PF), 1,000 mg/8 mL, Vial, 1	01/01/2022	22.83	136.98	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009001103	SOLU-CORTEF (hydrocortisone sodium succinate/PF), 100 mg / 2 mL, Vial, 1	01/01/2022	3.08	18.50	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009001104	SOLU-CORTEF (hydrocortisone sodium succinate/PF), 100 mg/2 mL, Vial, 1	01/01/2022	77.13	462.76	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009001305	SOLU-CORTEF (hydrocortisone sodium succinate/PF), 250 mg / 2 mL, Vial, 1	01/01/2022	5.71	34.24	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009001306	SOLU-CORTEF (hydrocortisone sodium succinate/PF), 250 mg/2 mL, Vial, 1	01/01/2022	142.66	855.96	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00009001612	SOLU-CORTEF (hydrocortisone sodium succinate/PF), 500 mg/4 mL, Vial, 1	01/01/2022	11.42	68.50	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069055038	SUTENT (sunitinib malate), 12.5 mg, CAPSULE, 1	01/01/2022	311.23	5969.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069077038	SUTENT (sunitinib malate), 25 mg, CAPSULE, 1	01/01/2022	622.45	11939.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069083038	SUTENT (sunitinib malate), 37.5 mg, CAPSULE, 1	01/01/2022	933.68	17909.66	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069098038	SUTENT (sunitinib malate), 50 mg, CAPSULE, 1	01/01/2022	1083.60	20785.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00005010010	TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg / 0.5 mL, SYRINGE (ML), 1	01/01/2022	108.05	1674.04	10/01/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on regulatory exclusivity.
Rx0000006	Pfizer	03/31/2022	00005010005	TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, SYRINGE (ML), 1	01/01/2022	54.02	837.02	10/01/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on regulatory exclusivity.
Rx0000006	Pfizer	09/30/2022	00409963305	Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr™ Plastic Syringe, 10	07/01/2022	55.50	610.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069019730	VIZIMPRO (dacomitinib), 15 mg, TABLET, 1	01/01/2022	751.91	14422.91	08/01/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application.
Rx0000006	Pfizer	03/31/2022	00069119830	VIZIMPRO (dacomitinib), 30 mg, TABLET, 1	01/01/2022	751.91	14422.91	08/01/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application.
Rx0000006	Pfizer	03/31/2022	00069229930	VIZIMPRO (dacomitinib), 45 mg, TABLET, 1	01/01/2022	751.91	14422.91	08/01/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. (4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application.
Rx0000006	Pfizer	03/31/2022	00069814120	XALKORI (crizotinib), 200 mg, CAPSULE, 1	01/01/2022	1022.26	19608.87	10/08/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069814020	XALKORI (crizotinib), 250 mg, CAPSULE, 1	01/01/2022	1022.26	19608.87	10/08/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069100201	XELJANZ (tofacitinib citrate), 10 mg, TABLET, 1	01/01/2022	271.18	5201.67	12/08/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069100101	XELJANZ (tofacitinib citrate), 5 mg, TABLET, 1	01/01/2022	271.18	5201.67	12/08/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2022	00069050130	XELJANZ XR (tofacitinib citrate), 11 mg, TABLET, EXTENDED RELEASE 24 HR, 1	01/01/2022	271.18	5201.67	12/08/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121050400	Acetaminophen & Codeine Phosphate CV 120mg/12mg, 5mL 100/cs	03/15/2022	111.30	234.97	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121100800	Acetaminophen & Codeine Phosphate CV 300mg/30mg, 12.5mL 100/cs	03/15/2022	131.22	277.02	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121064610	AMANTADINE HCL50 mg/5 mL, 10 TRAY in 1 CASE (0121-0646-10) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE	03/15/2022	106.95	320.85	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121097800	Diphenhydramine HCL 12.5mg/5mL (10mL), 10 TRAY in 1 CASE (0121-0978-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE (0121-0978-10)	03/15/2022	62.66	375.95	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121048900	Diphenhydramine HCL 12.5mg/5mL, 10 TRAY in 1 CASE (0121-0489-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-0489-05)	03/15/2022	80.60	379.13	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121065416	FLUPHENAZINE HCL2.5 mg/5 mL, 473 mL in 1 BOTTLE (0121-0654-16)	03/15/2022	66.36	255.96	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121157610	METOCLOPRAMIDE HCL10 mg/10 mL, 10 TRAY in 1 CASE (0121-1576-10) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE	03/15/2022	166.91	352.36	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121119000	Sodium Citrate/ Citric Acid 30 mL, 10 TRAY in 1 CASE (0121-1190-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 30 mL in 1 CUP, UNIT-DOSE (0121-1190-30)	03/15/2022	106.51	461.55	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121059500	Sodium Citrate/ Citric Acid, 10 TRAY in 1 CASE (0121-0595-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 15 mL in 1 CUP, UNIT-DOSE (0121-0595-15)	03/15/2022	98.15	425.33	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121085340	Sulfamethoxazole and Trimethoprim Oral Solution USP, 4 TRAY in 1 CASE (0121-0853-40) > 10 CUP, UNIT-DOSE in 1 TRAY > 20 mL in 1 CUP, UNIT-DOSE (0121-0853-20)	03/15/2022	91.77	397.68	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121135000	Valproic Acid Oral Solution, 10 TRAY in 1 CASE (0121-1350-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE (0121-1350-10)	03/15/2022	75.95	160.34	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121467500	Valproic Acid Oral Solution, 10 TRAY in 1 CASE (0121-4675-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-4675-05)	03/15/2022	41.63	87.88	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/31/2022	00121467540	Valproic Acid Oral Solution, 4 TRAY in 1 CASE (0121-4675-40) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-4675-05)	03/15/2022	26.61	56.18	None	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2022	57962014012	Imbruvica 120 Oral Capsule 140 MG	01/14/2022	1472.13	21365.82	10/24/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2022	57962007028	Imbruvica 28 Oral Capsule 70 MG	01/14/2022	1030.49	14956.08	10/24/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2022	57962001428	Imbruvica 28 Oral Tablet 140 MG	01/14/2022	1030.49	14956.08	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2022	57962028028	Imbruvica 28 Oral Tablet 280 MG	01/14/2022	1030.49	14956.08	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2022	57962042028	Imbruvica 28 Oral Tablet 420 MG	01/14/2022	1030.49	14956.08	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2022	57962056028	Imbruvica 28 Oral Tablet 560 MG	01/14/2022	1030.49	14956.08	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2022	57962014009	Imbruvica 90 Oral Capsule 140 MG	01/14/2022	1104.10	16024.37	10/24/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000289	Piramal Critical Care	09/30/2022	66794001725	Isoflurane Inhallation Solution 250 ml 1 bottle	07/01/2022	10.00	40.00	None	Non-innovator Multiple Source Drug	None	1	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000289	Piramal Critical Care	09/30/2022	66794001925	Terrell Isoflurane Inhallation Solution 250 ml 1 bottle	07/01/2022	10.00	40.00	None	Non-innovator Multiple Source Drug	None	1	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000347	Primus Pharmaceuticals Inc	12/31/2022	68040071338	IMPOYZ® External Cream; Clobetasol propionate 0.025%; Cream; 100g	11/21/2022	115.00	1350.00	08/31/2030	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000347	Primus Pharmaceuticals Inc	12/31/2022	68040071428	Sernivo® Spray; Betamethasone dipropionate 0.05%; Emulsion Spray; 120g in 1 bottle	11/21/2022	92.50	1090.00	08/31/2030	Single Source Drug	None	1	None	1	N/A	None	03/01/2021	Encore Dermatology	None	1	None	997.50	902.95	2017	859.95	None	None
Rx0000236	PTC Therapeutics, Inc	03/31/2022	52856050203	EMFLAZA (deflazacort) 18mg tabs/ 30 ct	01/17/2022	528.44	6465.94	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	3925.00	0.00	2017	3925.00	None	Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	09/30/2022	52856050203	EMFLAZA (deflazacort) 18mg tabs/30 ct	07/18/2022	607.79	7073.73	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	3925.00	0.00	2017	3925.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2022	52856050522	EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE	01/17/2022	386.80	4732.90	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	2873.00	0.00	2017	2873.00	None	Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	09/30/2022	52856050522	EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE	07/18/2022	444.89	5177.79	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	2873.00	0.00	2017	2873.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2022	52856050303	EMFLAZA (deflazacort) 30mg tabs/ 30 ct	01/17/2022	880.78	10777.11	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	6542.00	0.00	2017	6542.00	None	Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	09/30/2022	52856050303	EMFLAZA (deflazacort) 30mg tabs/30 ct	07/18/2022	1013.05	11790.16	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	6542.00	0.00	2017	6542.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2022	52856050403	EMFLAZA (deflazacort) 36mg tabs/ 30 ct	01/17/2022	1019.60	12475.73	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	7290.00	0.00	2017	7290.00	None	Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	09/30/2022	52856050403	EMFLAZA (deflazacort) 36mg tabs/30 ct	07/18/2022	1172.72	13648.45	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	7290.00	0.00	2017	7290.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2022	52856050101	EMFLAZA (deflazacort) 6mg tabs/100 ct	01/17/2022	587.13	7184.19	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	4361.00	0.00	2017	4361.00	None	Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	09/30/2022	52856050101	EMFLAZA (deflazacort) 6mg tabs/100 ct	07/18/2022	675.31	7859.50	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	4361.00	0.00	2017	4361.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000220	Puma Biotechnology, Inc.	03/31/2022	70437024018	Nerlynx Oral Tablet 40 mg, 180 tablet package	01/10/2022	900.00	19275.00	07/18/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	06/30/2022	59088017854	Pretrate, prenatal/ postnatal multivitamin, caplets, 30ct, Vitamin A 1500mcg, Vitamin C 120mg, Vitamin D3 20mcg, Vitamin E 30mg, Thiamin 3mg, Riboflavin 3.4mg, Niacin 20mg, Vitamin B6 50mg, Folate 1700mcg DFE, Vitamin B12 10mcg, Choline 55mg, Calcium 200mg, Iron 27mg, Iodine 150mcg, Magnesium 200mg, Zinc 25mg, Selenium 70mcg, Manganese 2.6mg, Chromium 45mcg, Molybdenum 50mcg	06/30/2022	220.00	1680.00	None	Single Source Drug	807	None	Raw material and labor	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000356	Radius Health, Inc.	03/31/2022	70539000101	TYMLOS 80 MCG Pen	01/01/2022	167.62	2289.34	01/10/2040	Single Source Drug	None	1	Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to: - The clinical and health outcomes value of our products to patients and payors. -  Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them. -  Responsible and competitive prices, in line with current treatment costs where other treatment options exist. - Corporate business strategy, including costs and profitability. -  Consideration of other factors such as Annual CPI-U rates. - R&D investment priorities and budgets to identify future medicines to improve the lives of patients -  Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000356	Radius Health, Inc.	03/31/2022	70539000102	TYMLOS 80 MCG Pen / Carton	01/01/2022	167.62	2289.34	01/10/2040	Single Source Drug	None	1	Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to: - The clinical and health outcomes value of our products to patients and payors. -  Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them. -  Responsible and competitive prices, in line with current treatment costs where other treatment options exist. - Corporate business strategy, including costs and profitability. -  Consideration of other factors such as Annual CPI-U rates. - R&D investment priorities and budgets to identify future medicines to improve the lives of patients -  Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292020111	Chemet 100 mg (Succimer), 100 caps/bottle	01/05/2022	164.88	2225.94	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292081155	Cosmegen Inj 0.5 mg (Dactinomycin for Injection), 0.5 mg/vial	01/05/2022	224.87	2473.55	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	52276040001	Cystadane (betaine anhydrous for oral solution) powder, 180 gm/bottle	01/05/2022	158.46	1826.43	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292010401	Desoxyn 5 mg (Methamphetamine hydrochloride), 100 tab/bottle	01/05/2022	187.19	2059.08	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292032020	Isturisa (osilodrostat) 1 mg, 20 tablet	01/05/2022	125.90	2643.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292032060	Isturisa (osilodrostat) 1 mg, 60 tablet	01/05/2022	377.69	7931.39	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	12/31/2022	55292032020	Isturisa Oral Tablet 1 MG Package Size 20	11/01/2022	251.16	2894.96	10/12/2035	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	0	1	None	1.00	0.00	2020	2200.00	None	The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020.
Rx0000363	Recordati Rare Diseases, inc.	12/31/2022	55292032220	Isturisa Oral Tablet 10 MG Package Size 20	11/01/2022	1005.34	11587.82	10/12/2035	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	0	1	None	1.00	0.00	2020	9500.00	None	The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020.
Rx0000363	Recordati Rare Diseases, inc.	12/31/2022	55292032260	Isturisa Oral Tablet 10MG Package Size 60	11/01/2022	3016.01	34763.44	10/12/2035	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	0	1	None	1.00	0.00	2020	28500.00	None	The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020.
Rx0000363	Recordati Rare Diseases, inc.	12/31/2022	55292032060	Isturisa Oral Tablet 1MG Package Size 60	11/01/2022	753.48	8684.87	10/12/2035	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	0	1	None	1.00	0.00	2020	6600.00	None	The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020.
Rx0000363	Recordati Rare Diseases, inc.	12/31/2022	55292032120	Isturisa Oral Tablet 5 MG Package Size 20	11/01/2022	846.60	9758.16	10/12/2035	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	0	1	None	1.00	0.00	2020	8000.00	None	The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020.
Rx0000363	Recordati Rare Diseases, inc.	12/31/2022	55292032160	Isturisa Oral Tablet 5MG Package Size 60	11/01/2022	2539.79	29274.47	10/12/2035	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	0	1	None	1.00	0.00	2020	24000.00	None	The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020.
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292012252	NeoProfen Inj (Ibuprofen lysine), 2 ml/vial, 3 vials	01/05/2022	268.25	2950.77	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292070255	Panhematin Inj 350 mg (Hemin for Injection), 48 ml/vial	01/05/2022	775.20	9388.51	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	55292013901	SIGNIFOR LAR Intra-muscular Suspension 10 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2018	13058.40	None	Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market.
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078074881	Signifor LAR Intramuscular Suspension 10 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2018	12308.00	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	55292014001	SIGNIFOR LAR Intra-muscular Suspension 20 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2014	13058.40	None	Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market.
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078064181	Signifor LAR Intramuscular Suspension 20 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2014	10769.23	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	55292014101	SIGNIFOR LAR Intra-muscular Suspension 30 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2018	13058.40	None	Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market.
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078074181	Signifor LAR Intramuscular Suspension 30 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2018	12308.00	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	55292014201	SIGNIFOR LAR Intra-muscular Suspension 40 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2014	13058.40	None	Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market.
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078064281	Signifor LAR Intramuscular Suspension 40 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2014	10769.23	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	55292014301	SIGNIFOR LAR Intra-muscular Suspension 60 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2014	13058.40	None	Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market.
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078064381	Signifor LAR Intramuscular Suspension 60 mg - 1 Kit	08/01/2022	584.10	15186.66	05/23/2028	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	12678.06	12308.80	2014	10769.23	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078063320	Signifor Subcutaneous Solution 0.3mg/1mL - 60 ampules - 1 Box	08/01/2022	615.32	15998.29	12/14/2026	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	13546.42	13151.86	2012	14383.56	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078063420	Signifor Subcutaneous Solution 0.6mg/1mL - 60 ampules - 1 Box	08/01/2022	615.32	15998.29	12/14/2026	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	13546.42	13151.86	2012	14383.56	None	None
Rx0000363	Recordati Rare Diseases, inc.	09/30/2022	00078063520	Signifor Subcutaneous Solution 0.9mg/1mL - 60 ampules - 1 Box	08/01/2022	615.32	15998.29	12/14/2026	Single Source Drug	None	1	None	1	None	1	07/12/2019	Novartis	None	1	None	13546.42	13151.86	2012	14383.56	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2022	55292030401	Tranxene T-Tab 7.5 mg (Clorazepate dipotassium), 100 tabs/bottle	01/05/2022	130.46	1435.04	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	06/30/2022	71332000101	Tavalisse 100 mg oral tablet 60 count	04/25/2022	620.00	13020.00	07/27/2032	Single Source Drug	None	1	Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	06/30/2022	71332000201	Tavalisse 150 mg oral tablet 60 count	04/25/2022	620.00	13020.00	07/27/2032	Single Source Drug	None	1	Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000321	R-Pharm US, LLC	03/31/2022	70020191001	IXEMPRA Kit 15mg	01/01/2022	33.15	1690.65	11/01/2025	Single Source Drug	5100	None	Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services.	None	None	1	01/01/2016	BMS	1080	None	None	1080.00	1080.00	2007	1080.00	None	None
Rx0000321	R-Pharm US, LLC	03/31/2022	70020191101	IXEMPRA Kit 45mg	01/01/2022	99.45	5071.95	11/01/2025	Single Source Drug	2670	None	Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services.	None	None	1	01/01/2016	BMS	3241	None	None	3241.00	3241.00	2007	3241.00	None	None
Rx0000385	Sagent Pharmaceuticals	06/30/2022	25021011482	Ciprofloxacin/Dextrose 5% (2mg/ml, 100ml, 24x100ml)	04/28/2022	22.06	72.00	None	Non-innovator Multiple Source Drug	1000	None	Sagent does not have sales to report as this is a re-launch	None	N/A	None	None	None	None	None	None	None	None	None	None	None	The WAC price was lowered in December 2010 to $49.94. Due to increased competition and pricing pressures, we had to discontinue sales for this product in January 2012. Ten years after that sales discontinuation, we have decided to bring this product back to market, and re-launched this product in May 2022. The WAC price is $72.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649041112	ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 12	01/01/2022	53.63	732.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649041124	ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 24	01/01/2022	107.27	1465.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649040130	ANUSOl-HC® (Hydrocortisone Cream, USP) 2.5%, 30gm	01/01/2022	12.05	164.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649024141	AZASAN® (Azathioprine Tablets, USP) 100mg, 100ct	01/01/2022	67.55	922.59	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649023141	AZASAN® (Azathioprine Tablets, USP) 75mg, 100ct	01/01/2022	151.51	2069.39	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649020175	MOVIPREP® (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution), 1 Kit	01/01/2022	7.12	125.88	09/01/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649070141	OSMOPREP® (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) 1.5g Tablets, 100	01/01/2022	60.98	832.81	06/22/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649040001	PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), Kit	01/01/2022	7.41	131.01	09/10/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649055102	RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial	01/01/2022	10.62	145.14	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649055103	RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct	01/01/2022	74.39	1015.98	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649055107	RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial	01/01/2022	10.62	145.14	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649055204	RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct	01/01/2022	74.39	1015.98	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649015090	RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct	01/01/2022	159.40	2177.15	03/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649000330	Trulance® (plecanatide) 3mg Tablets, 30	01/01/2022	37.21	508.18	06/05/2034	Single Source Drug	None	1	None	1	None	1	03/01/2019	Synergy Pharmaceuticals Inc.	None	1	Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003808	411.78	388.47	2017	353.48	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	70194000330	Trulance® (plecanatide) 3mg Tablets, Blister Pack of 30	01/01/2022	37.21	508.18	06/05/2034	Single Source Drug	None	1	None	1	None	1	03/01/2019	Synergy Pharmaceuticals Inc.	None	1	Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003809	411.78	388.47	2017	353.48	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649065103	UCERIS® (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation	01/01/2022	55.71	760.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649030303	XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card	01/01/2022	217.84	2975.32	10/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2022	65649030302	XIFAXAN® (rifaximin) 550mg Tablets, 60ct	01/01/2022	217.84	2975.32	10/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000011	Sanofi	03/31/2022	58468021002	AUBAGIO (teriflunomide) 14 mg tablet - blister pack of 28	01/03/2022	428.75	7950.68	09/14/2030	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine LIMITED U.S. PRICE INCREASES on our medicines over time CONTINUED TRANSPAR­­­ENCY IN THE U.S. around our pricing decisions   When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.   We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year.   Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2022	58468021004	AUBAGIO (teriflunomide) 14 mg tablet - bottle of 30	01/03/2022	459.38	8518.60	09/14/2030	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine LIMITED U.S. PRICE INCREASES on our medicines over time CONTINUED TRANSPAR­­­ENCY IN THE U.S. around our pricing decisions   When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.   We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year.   Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2022	58468021101	AUBAGIO (teriflunomide) 7 mg tablet - blister pack of 28	01/03/2022	427.75	7950.68	09/14/2030	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine LIMITED U.S. PRICE INCREASES on our medicines over time CONTINUED TRANSPAR­­­ENCY IN THE U.S. around our pricing decisions   When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.   We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year.   Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2022	58468021104	AUBAGIO (teriflunomide) 7 mg tablet - bottle of 30	01/03/2022	459.38	8518.60	09/14/2030	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine LIMITED U.S. PRICE INCREASES on our medicines over time CONTINUED TRANSPAR­­­ENCY IN THE U.S. around our pricing decisions   When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.   We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year.   Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	09/30/2022	00024515010	Elitek (rasburicase) 1.5 mg/ml 3 vials + 3 ampules	07/01/2022	80.47	3037.91	None	Single Source Drug	None	1	In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain. For more information on our pricing principles, please download our 2022 report: https://www.sanofi.us/en/corporate-responsibility/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	09/30/2022	00024515175	Elitek (rasburicase) 7.5 mg/ml 1 vial + 1 ampule	07/01/2022	134.13	5063.18	None	Single Source Drug	None	1	In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain. For more information on our pricing principles, please download our 2022 report: https://www.sanofi.us/en/corporate-responsibility/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	09/30/2022	00024582411	Jevtana (cabazitaxel) 60 mg vial 1.5 ml carton	07/01/2022	291.01	12816.67	None	Single Source Drug	None	1	In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain. For more information on our pricing principles, please download our 2022 report: https://www.sanofi.us/en/corporate-responsibility/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2022	00024592001	KEVZARA (sarilumab) 150 mg/1.14 mL pen - carton of 2 pens	01/03/2022	208.44	3865.35	12/06/2031	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine LIMITED U.S. PRICE INCREASES on our medicines over time CONTINUED TRANSPAR­­­ENCY IN THE U.S. around our pricing decisions   When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.   We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year.   Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2022	00024590801	KEVZARA (sarilumab) 150 mg/1.14 mL syringe - carton of 2 syringes	01/03/2022	208.44	3865.35	12/06/2031	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: • CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine • LIMITED U.S. PRICE INCREASES on our medicines over time • CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch. We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2022	00024592201	KEVZARA (sarilumab) 200 mg/1.14 mL pen - carton of 2 pens	01/03/2022	208.44	3865.35	12/06/2031	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine LIMITED U.S. PRICE INCREASES on our medicines over time CONTINUED TRANSPAR­­­ENCY IN THE U.S. around our pricing decisions   When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch.   We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year.   Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2022	00024591001	KEVZARA (sarilumab) 200 mg/1.14 mL syringe - carton of 2 syringes	01/03/2022	208.44	3865.35	12/06/2031	Single Source Drug	None	1	While many factors, including decisions affecting patient out-of-pocket spending and insurance coverage, are controlled by other stakeholders in the health care system, we believe we have a responsibility to be a leader in solving issues of patient access and system viability. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. health care system. Sanofi’s commitment to pricing rests on three principles: • CLEAR RATIONALE FOR PRICING at the time of launch of a new medicine • LIMITED U.S. PRICE INCREASES on our medicines over time • CONTINUED TRANSPARENCY IN THE U.S. around our pricing decisions When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes a holistic assessment of value, including 1) clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care; 2) economic value, or how the medicine reduces the need – and therefore costs – of other health care interventions; and 3) social value, or how the medicine contributes to quality of life and productivity. Our assessments rely on a range of internal and external methodologies, including health technology assessment (HTA) and other analyses that help define or quantify value and include patient perspectives and priorities. Similar treatment options available or anticipated at the time of launch, in order to understand the landscape within the disease areas in which the medicine may be used. Affordability, including the steps we must take to promote access for patients and contribute to a more sustainable system for payors and health care systems. Unique factors specific to the medicine at the time of launch. We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures (NHE) for said year. Our benchmark, the projected U.S. NHE growth rate, is estimated and published annually by the Centers for Medicare & Medicaid Services (CMS). The NHE projection provides a critical forward-looking view needed for business planning. NHE measures spending across all health care goods and services and reflects payments made by both public and private payors. Once the NHE projection is updated each year, we will adjust any future planned pricing actions to reflect the projection. Given the need for business planning, we will adopt the updated standard by April 1 each year.	None	See Column 10 Cost Increase Factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000092	Santarus, Inc.	03/31/2022	68012025820	CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct	01/01/2022	75.78	1035.08	04/30/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000035	Saol Therapeutics Inc	03/31/2022	70257053251	Cytomegalovirus Immune Globulin Intravenous (Human), 1 single dose vial (50 mL)	01/03/2022	131.85	1613.27	None	Single Source Drug	None	1	None	1	None	1	08/06/2019	CSL Behring	None	1	None	1285.00	1285.00	1998	1164.00	None	We do not have the WAC at Intro to Market for CytoGam. MedImmune was the company that first marketed the product. 2011 price of $1,164.00 is the oldest price we have.
Rx0000035	Saol Therapeutics Inc	03/31/2022	70257012651	VARIZIG, single dose vial of 125 IU in 1.2mL	01/03/2022	111.66	2004.20	None	Single Source Drug	None	1	None	1	None	1	09/27/2017	Aptevo Therapeutics	None	1	None	1306.34	1185.00	2012	682.50	None	Varizig introduced to the market in 2012 as lyophilized powder. Current formulation is liquid. Patent Exp. Date: N/A (Biologic status)
Rx0000086	Seagen, Inc.	12/31/2022	51144005001	ADCETRIS, 50mg, single-dose vial, packaged singly	12/29/2022	392.00	10470.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product.
Rx0000086	Seagen, Inc.	09/30/2022	51144002001	PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution	09/29/2022	95.00	2552.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000086	Seagen, Inc.	09/30/2022	51144003001	PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution	09/29/2022	142.50	3828.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000086	Seagen, Inc.	12/31/2022	51144000212	TUKYSA, 150mg, 120 Count Oral Tablet per Bottle	12/29/2022	1938.00	23514.00	04/27/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b).  (2) The patent expiration date listed reflects the latest expiring of certain granted patents that currently cover TUKYSA.   Additional patents may be granted from existing and future patent applications and may have different expiry dates.  The expiry date listed is based on current assumptions and existing information; patent expiry dates are subject to change.  (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product.
Rx0000086	Seagen, Inc.	12/31/2022	51144000260	TUKYSA, 150mg, 60 Count Oral Tablet per Bottle	12/29/2022	969.00	11757.00	04/27/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b).  (2) The patent expiration date listed reflects the latest expiring of certain granted patents that currently cover TUKYSA.   Additional patents may be granted from existing and future patent applications and may have different expiry dates.  The expiry date listed is based on current assumptions and existing information; patent expiry dates are subject to change.  (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product.
Rx0000086	Seagen, Inc.	12/31/2022	51144000160	TUKYSA, 50mg, 60 Count Oral Tablet per Bottle	12/29/2022	482.00	5847.00	04/27/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b).  (2) The patent expiration date listed reflects the latest expiring of certain granted patents that currently cover TUKYSA.   Additional patents may be granted from existing and future patent applications and may have different expiry dates.  The expiry date listed is based on current assumptions and existing information; patent expiry dates are subject to change.  (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product.
Rx0000086	Seattle Genetics, Inc.	06/30/2022	51144005001	ADCETRIS, 50mg, single-dose vial, packaged singly	06/30/2022	378.00	10078.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product.
Rx0000086	Seattle Genetics, Inc.	03/31/2022	51144002001	PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution	03/31/2022	92.00	2457.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000086	Seattle Genetics, Inc.	03/31/2022	51144003001	PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution	03/31/2022	138.00	3685.50	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000121	Secura Bio, Inc.	06/30/2022	71779011502	Copiktra 15 mg 56-count capsules	04/04/2022	1628.16	18074.31	01/10/2032	Single Source Drug	None	1	None	1	None	1	09/30/2020	Verastem, Inc.	311000000	None	None	12390.00	11800.00	2018	11800.00	None	None
Rx0000121	Secura Bio, Inc.	12/31/2022	71779011502	Copiktra 15 mg oral capsule, 56 caps per package	11/14/2022	5949.45	24020.76	05/17/2032	Single Source Drug	None	1	None	1	None	1	09/30/2020	Verastem, Inc.	70000000	None	None	12390.00	11800.00	2018	11800.00	None	None
Rx0000121	Secura Bio, Inc.	06/30/2022	71779012502	Copiktra 25 mg 56-count capsules	04/04/2022	1628.16	18074.31	01/10/2032	Single Source Drug	None	1	None	1	None	1	09/30/2020	Verastem, Inc.	311000000	None	None	12390.00	11800.00	2018	11800.00	None	None
Rx0000121	Secura Bio, Inc.	12/31/2022	71779012502	Copiktra 25 mg oral capsule, 56 caps per package	11/14/2022	5949.45	24020.76	05/17/2032	Single Source Drug	None	1	None	1	None	1	09/30/2020	Verastem, Inc.	70000000	None	None	12390.00	11800.00	2018	11800.00	None	None
Rx0000121	Secura Bio, Inc.	12/31/2022	73116022556	Copiktra 25 mg oral capsule, 56 caps per package. Secura Bio labeler code	11/14/2022	5949.45	24020.76	05/17/2032	Single Source Drug	None	1	None	1	None	1	09/30/2020	Verastem, Inc.	70000000	None	None	12390.00	11800.00	2018	11800.00	None	None
Rx0000028	Servier Pharmaceuticals LLC	03/31/2022	72694095401	Oncaspar Injection Solution 750 Unit/ML, 5 ML, Unit-Dose, Vial	01/01/2022	1901.85	22242.46	None	Single Source Drug	None	1	The increase of wholesale Acquisition Cost (WAC) for the product is due to increases in many factors that could include the cost of manufacturing and distribution, increases in the cost of ingredients, increases in shipping for the product and increases in the costs to market the product. There are many other non-financial factors that have impacted the decision including COVID-19, company structure, market access and others.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000376	Stemline Therapeutics	09/30/2022	72187040101	ELZONRIS 1,000mcg/mL, VIAL (ML), 1	07/15/2022	5.00	30912.68	06/29/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Stemline considers many factors in determining the price of its product, ELZONRIS, including Stemline’s post-marketing regulatory obligations associated with the product, ongoing pharmacovigilance, costs associated with the cold chain distribution process, and market conditions and dynamics. Recently, increasing rates of inflation have been a significant consideration for Stemline. (2) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Stemline believes is otherwise in the public domain or publicly available. Where possible, Stemline has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (3) For Columns 14-22, Stemline has not provided a response as the compound was acquired from an unrelated company more than 5 years ago.
Rx0000165	Supernus Pharmaceuticals, Inc.	09/30/2022	27505000401	Apokyn Subcutaneous Solution Cartridge 30 MG/3ML	07/01/2022	86.43	1321.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	09/30/2022	27505000405	Apokyn Subcutaneous Solution Cartridge 30 MG/3ML Cartridge Qty 5	07/01/2022	432.14	6605.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772012101	Oxtellar XR 150mg X 100, capsule	01/01/2022	45.49	803.59	04/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772012201	Oxtellar XR 300mg X 100, capsule	01/01/2022	63.19	1116.40	04/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772012301	Oxtellar XR 600mg X 100, capsule	01/01/2022	115.70	2044.02	04/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010330	Trokendi XR 100mg X 30, capsule	01/01/2022	50.84	898.16	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010301	Trokendi XR 100mg X100, capsule	01/01/2022	169.47	2993.89	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010430	Trokendi XR 200mg X 30, capsule	01/01/2022	69.55	1228.64	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010401	Trokendi XR 200mg X100, capsule	01/01/2022	231.82	4095.42	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010130	Trokendi XR 25mg X 30, capsule	01/01/2022	19.70	348.01	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010101	Trokendi XR 25mg X100, capsule	01/01/2022	65.66	1160.04	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010230	Trokendi XR 50mg X 30, capsule	01/01/2022	25.66	453.31	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2022	17772010201	Trokendi XR 50mg X100, capsule	01/01/2022	85.53	1511.07	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	09/30/2022	27505011130	Xadago Oral Tablet 100 MG	07/01/2022	78.15	1055.08	03/21/2031	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	09/30/2022	27505011030	Xadago Oral Tablet 50 MG	07/01/2022	78.15	1055.08	03/21/2031	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2022	64764030020	Entyvio 300mg 20mL Vial	01/04/2022	436.60	7713.23	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000232	TerSera Therapeutics LLC	03/31/2022	70720012585	(New Labeler Code) XERMELO (telostristat ethyl), Oral Tablet, 250mg, 1 Case/84 Tablets	01/01/2022	370.52	7932.07	02/27/2031	Single Source Drug	None	1	None	1	None	1	09/08/2020	Lexicon Pharmaceuticals, Inc	159000000	None	" Lexicon received approximately $159M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer."	6559.00	5961.00	2017	5164.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. This product's NDC description matches another product inside this manufacturers submissions, but the NDCs are different. This is due to the manufacturer acquiring the product and then changing the NDC to their labeler code in the past few months.
Rx0000232	TerSera Therapeutics LLC	03/31/2022	70720095036	ZOLADEX (goserelin implant), 3.6mg, 1 Syringe	01/01/2022	36.60	783.61	04/13/2022	Single Source Drug	None	1	None	1	None	1	04/06/2018	AztraZeneca	320000000	None	AstraZeneca received a $250m upfront payment for the rights of Zoladex, with double-digit quarterly sales-based payments being recieved on an ongoing basis. A further $70m was also in the sell should Zoladex meet a series of sales-related milestones	605.00	550.50	1989	265.63	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000217	Teva Neuroscience, Inc.	03/31/2022	68546017260	AUSTEDO TABLETS 12MG 60	01/01/2022	485.37	6629.90	09/15/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2022	68546017060	AUSTEDO TABLETS 6MG 60	01/01/2022	323.60	4419.90	09/15/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2022	68546017160	AUSTEDO TABLETS 9MG 60	01/01/2022	364.10	4972.40	09/15/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2022	68546014256	AZILECT TABLET 0.5MG 30	01/01/2022	85.60	996.50	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2022	68546022956	AZILECT TABLET1MG 30	01/01/2022	85.60	996.50	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459051230	ACTIQ Lozenge 1200MCG 30	01/01/2022	537.60	6256.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459051630	ACTIQ Lozenge 1600MCG 30	01/01/2022	663.20	7718.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459050230	ACTIQ Lozenge 200MCG 30	01/01/2022	225.30	2621.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459050430	ACTIQ Lozenge 400MCG 30	01/01/2022	285.10	3318.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459050830	ACTIQ Lozenge 800MCG 30	01/01/2022	413.60	4813.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459050630	ACTIQ Lozenge 600MCG 30	01/01/2022	349.40	4066.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844011001	ADDERALL TABLET 10MG 100	01/01/2022	77.03	896.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844012001	ADDERALL TABLET 20MG 100	01/01/2022	77.03	896.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844013001	ADDERALL TABLET 30MG 100	01/01/2022	77.03	896.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844011201	ADDERALL TABLET12.5MG 100	01/01/2022	77.03	896.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844011501	ADDERALL TABLET15MG 100	01/01/2022	77.03	896.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844010501	ADDERALL TABLET5MG 100	01/01/2022	77.03	896.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844011701	ADDERALL TABLET7.5MG 100	01/01/2022	77.03	896.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459070060	AMRIX ORAL CAPSULE ER 15 MG 60	01/01/2022	260.70	3034.50	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459070160	AMRIX ORAL CAPSULE ER 30 MG 60	01/01/2022	260.70	3034.50	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459054128	FENTORA TABLET 100MCG 28	01/01/2022	164.90	1918.90	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459054228	FENTORA TABLET 200MCG 28	01/01/2022	208.30	2424.40	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459054428	FENTORA TABLET 400MCG 28	01/01/2022	302.30	3517.80	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459054628	FENTORA TABLET 600MCG 28	01/01/2022	392.40	4567.00	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459054828	FENTORA TABLET 800MCG 28	01/01/2022	483.40	5626.40	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	52544008001	FIORICET CAPSULE 50/300/40MG 100	01/01/2022	56.00	652.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	52544008201	FIORICET/CODEINE CAPSULE 50/300/40/30MG 100	01/01/2022	117.30	1365.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	00093360882	FLUTIC/SALMET INH PWD 113/14MCG 60 DOSE	02/07/2022	21.60	117.00	04/06/2035	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	00093360982	FLUTIC/SALMET INH PWD 232/14MCG 60 DOSE	02/07/2022	21.60	117.00	04/06/2035	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	00093360782	FLUTICA/SALMET INH PWD 55-14MCG 60 DOSE	02/07/2022	21.60	117.00	04/06/2035	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459041230	GABITRIL TABLET 12MG 30	01/01/2022	39.70	461.90	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459040230	GABITRIL TABLET 2MG 30	01/01/2022	30.70	357.30	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459040430	GABITRIL TABLET 4MG 30	01/01/2022	30.70	357.30	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459041630	GABITRIL TABLET16MG 30	01/01/2022	52.00	604.80	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844021552	GALZIN CAPSULE 25MG 250	01/01/2022	40.70	474.10	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	57844020852	GALZIN CAPSULE 50MG 250	01/01/2022	67.90	790.10	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	16252053901	ISRADIPINE 2.5MG CAPSULES 100	01/17/2022	47.40	144.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	16252054001	ISRADIPINE 5MG CAPSULES 100	01/17/2022	69.29	211.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459021530	NUVIGIL TABLET 150MG 30	01/01/2022	87.10	1013.50	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459022030	NUVIGIL TABLET 200MG 30	01/01/2022	87.10	1013.50	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459022530	NUVIGIL TABLET 250MG 30	01/01/2022	87.10	1013.50	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459020530	NUVIGIL TABLET 50MG 30	01/01/2022	28.90	336.80	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	00575620030	PROGLYCEM ORAL SUSPENSION 50MG/ML 30ML/ 1 BOTTLE	01/01/2022	32.40	376.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459010130	PROVIGIL TABLET 100MG 30	01/01/2022	121.90	1418.30	05/29/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459020130	PROVIGIL TABLET 200MG 30	01/01/2022	184.10	2142.90	05/29/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459017714	SYNRIBO INJECTION 3.5 MG	01/01/2022	104.50	1216.50	10/26/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2022	63459060106	TRISENOX VIAL 2 MG/ML 6 ML	01/01/2022	916.30	10663.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2022	59310081206	AIRDUO 113-14MCG 60 ACT /inhaler	01/01/2022	32.97	383.30	04/06/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2022	59310082206	AIRDUO 232-14MCG 60 ACT/ inhaler	01/01/2022	32.97	383.30	04/06/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2022	59310080506	AIRDUO 55-14MCG 60 ACT /inhaler	01/01/2022	32.97	383.30	04/06/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2022	59310040606	QNASL PLV INHALER 40MCG 60/ACT TRADE /1 inhaler	01/01/2022	24.21	281.73	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2022	59310041012	QNASL PLV INHALER 80MCG 120/ACT TRADE/ 1 inhaler	01/01/2022	24.21	281.73	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285042410	AYGESTIN TABLET 5MG 50	01/01/2022	26.10	303.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285012870	LOESTRIN FE TABLET 28 1.5MG/30MCG 140	01/01/2022	72.40	842.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285012570	LOESTRIN FE TABLET 28 1MG/20MCG 140	01/01/2022	72.40	842.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285013197	LOESTRIN TABLET 21 1.0MG/20MCG 105	01/01/2022	72.40	842.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285012797	LOESTRIN TABLET 21 1.5MG/30MCG 105	01/01/2022	72.40	842.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285009287	LOSEASONIQUE TABLET 0.1-0.02 & 0.01 MG 182	01/01/2022	84.10	979.20	12/05/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285012058	MIRCETTE TABLET 28 .15MG/.02MG .01MG	01/01/2022	90.70	1055.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285006390	PREFEST TABLET 1/1-0.09 MG 180	01/01/2022	92.30	1074.70	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285043187	QUARTETTE TABLET 42-21-21-7 DAYS 182	01/01/2022	100.80	1172.70	03/11/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285008787	SEASONIQUE TABLET 0.15-0.03 &0.01 MG 182	01/01/2022	84.10	979.20	12/05/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285036801	TREXALL TABLET 10MG 30	01/01/2022	90.80	1056.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285036901	TREXALL TABLET 15MG 30	01/01/2022	136.20	1585.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285036601	TREXALL TABLET 5MG 30	01/01/2022	45.40	528.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285036701	TREXALL TABLET 7.5MG 30	01/01/2022	68.10	792.70	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285004001	ZIAC TABLET 10MG/6.25MG 30	01/01/2022	21.20	247.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285004702	ZIAC TABLET 2.5MG/6.25MG 100	01/01/2022	70.70	823.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2022	51285005002	ZIAC TABLET 5MG/6.25MG 100	01/01/2022	70.70	823.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000134	Therakos, Inc.	03/31/2022	64067021601	UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML	01/01/2022	576.00	6974.00	None	Single Source Drug	None	1	This price is not reflective of discounts available to customers. This increase is the result of increased costs and other financial commitments of the company, including the recent launch of a new biologic therapy to treat adults with deep partial-thickness burns and the potential launch of another therapy later this year. Mallinckrodt continues to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness.	None	This price is not reflective of discounts available to customers. This increase is the result of increased costs and other financial commitments of the company, including the recent launch of a new biologic therapy to treat adults with deep partial-thickness burns and the potential launch of another therapy later this year. Mallinckrodt continues to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness.	None	None	None	None	None	None	None	None	None	None	None	This price information is reflective of the case unit of sale of the product. Uvadex is used only for extracorporeal photopheresis (ECP) therapy and is administered by a healthcare professional in a clinical setting.
Rx0000057	Theratechnologies Inc.	03/31/2022	62064024130	EGRIFTA SV 2MG LYO PWD 30/PAC	01/01/2022	367.00	6491.00	05/01/2023	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000057	Theratechnologies Inc.	03/31/2022	62064012202	TROGARZO 150MG/ML 1.33ML SDV 2/PAC	01/01/2022	127.00	2676.00	04/01/2030	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000183	Tris Pharma, Inc	03/31/2022	27808010201	Dyanavel XR 2.5mg/mL Suspension 464mL Bottle	01/03/2022	38.54	1341.99	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2022	50474070062	CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS	01/01/2022	284.12	5099.68	02/13/2024	Single Source Drug	1398306000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2022	50474071079	CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES	01/01/2022	284.12	5099.68	02/13/2024	Single Source Drug	1398306000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2022	50474071081	CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES	01/01/2022	852.35	15299.03	02/13/2024	Single Source Drug	1398306000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794010201	Crysvita 10 mg/mL Subcutaneous Injection 1 Carton	08/01/2022	116.00	3997.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794020301	Crysvita 20 mg/mL Subcutaneous Injection 1 Carton	08/01/2022	232.00	7994.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794030401	Crysvita 30 mg/mL Subcutaneous Injection 1 Carton	08/01/2022	348.00	11991.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794000101	Mepsevii 10 mg/5mL (2mg/mL) Intravenous Injection 1 Carton	08/01/2022	72.00	2486.00	03/05/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000036	United Therapeutics	12/31/2022	66302020603	Tyvaso Inhalation Solution 0.6 mg/mL Package of 4 Kits	10/01/2022	132.99	2847.08	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	12/31/2022	66302020602	Tyvaso Refill Inhalation Solution 0.6 mg/mL Package of 28 Kits	10/01/2022	930.93	19929.60	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	12/31/2022	66302020604	Tyvaso Starter Inhalation Solution 0.6 mg/mL Package of 4 Kits	10/01/2022	240.56	5150.05	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	12/31/2022	66302020601	Tyvaso Starter Inhalation Solution 0.6 mg/mL Package of 28 Kits	10/01/2022	1038.50	22232.58	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	03/31/2022	66302001401	Unituxin Dinutuximab; 17.5mg/5mL; Injection/vial; 5mL vial	01/01/2022	1292.64	14349.60	03/01/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Pricing decision was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068011304	Iloperidone 1 & 2 & 4 & 6 MG Tablet 8 EA	07/16/2022	18.32	233.84	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068010102	Iloperidone 1 MG Tablet 60 EA	07/16/2022	137.38	1753.63	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068011002	Iloperidone 10 MG Tablet 60 EA	07/16/2022	270.71	3455.52	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068011202	Iloperidone 12 MG Tablet 60 EA	07/16/2022	270.71	3455.52	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068010202	Iloperidone 2 MG Tablet 60 EA	07/16/2022	137.38	1753.63	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068010402	Iloperidone 4 MG Tablet 60 EA	07/16/2022	137.38	1753.63	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068010602	Iloperidone 6 MG Tablet 60 EA	07/16/2022	169.04	2157.74	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068010802	Iloperidone 8 MG Tablet 60 EA	07/16/2022	169.04	2157.74	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068022001	Tasimelteon 20 MG Capsule 30 EA	07/16/2022	1865.22	23808.98	08/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068030406	Tasimelteon 4 MG/ML Suspension 158 ML	07/16/2022	1964.70	25078.79	12/11/2040	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	09/30/2022	43068030402	Tasimelteon 4 MG/ML Suspension 48 ML	07/16/2022	596.87	7618.87	12/11/2040	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2022	68992307501	Envarsus XR .75mg 100 Tab	12/23/2022	16.10	475.88	08/30/2028	Single Source Drug	31741	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2022	68992307503	Envarsus XR .75mg 30 Tab	12/23/2022	4.83	142.77	08/30/2028	Single Source Drug	54789	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2022	68992301001	Envarsus XR 1mg 100 Tab	12/23/2022	21.46	634.51	08/30/2028	Single Source Drug	159730	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2022	68992301003	Envarsus XR 1mg 30 Tab	12/23/2022	6.44	190.36	08/30/2028	Single Source Drug	231804	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2022	68992304001	Envarsus XR 4mg 100 Tab	12/23/2022	85.84	2538.00	08/30/2028	Single Source Drug	47258	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2022	68992304003	Envarsus XR 4mg 30 Tab	12/23/2022	25.76	761.40	08/30/2028	Single Source Drug	82394	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000450	Vericel Corporation	12/31/2022	69866103005	MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3)	10/01/2022	3646.00	52252.00	11/25/2033	Single Source Drug	None	1	The Company is implementing this price increase to account for inflation and mitigate its rising cost of goods including the increased costs of materials from suppliers.	None	No improvement.	None	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021.
Rx0000450	Vericel Corporation	12/31/2022	69866103008	MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX (69866-1030-8) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6)	10/01/2022	7292.00	104504.00	11/25/2033	Single Source Drug	None	1	The Company is implementing this price increase to account for inflation and mitigate its rising cost of goods including the increased costs of materials from suppliers.	None	No improvement.	None	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000450	Vericel Corporation	06/30/2022	69866103008	MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6)	06/17/2022	34664.00	97212.00	11/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025005230	Corvite 150 30 CT	09/03/2022	11.96	161.41	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025006030	Corvite Fe 30 CT	09/03/2022	15.73	212.31	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025006530	Divigel 0.1% 0.25 mg	09/03/2022	6.57	168.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025006630	Divigel 0.1% 0.5 mg	09/03/2022	6.57	168.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025008330	Divigel 0.1% 0.75 mg	09/03/2022	6.57	168.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025006730	Divigel 0.1% 1.0 mg	09/03/2022	6.57	168.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025008630	Divigel 0.1% 1.25 mg	09/03/2022	6.57	168.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025001010	OB Complete 100 CT	09/03/2022	20.76	280.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025004960	OB Complete DHA 60 CT	09/03/2022	16.38	220.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025004430	OB Complete One 30 CT	09/03/2022	16.61	224.23	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025005930	OB Complete Petite 30 CT	09/03/2022	16.82	227.01	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000155	Vertical Pharmaceuticals, LLC	09/30/2022	68025004330	OB Complete Premier 30 CT	09/03/2022	11.64	157.15	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Vertical
Rx0000414	Vifor Pharma Inc.	06/30/2022	53436008404	Veltassa® (patiromer sorbitex calcium powder), for oral suspension 4 packets 8.4 grams	04/01/2022	4.20	172.10	10/08/2033	Single Source Drug	None	1	Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive.	None	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=660	None
Rx0000414	Vifor Pharma Inc.	06/30/2022	53436016830	Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 16.8 grams	04/01/2022	23.56	965.92	10/08/2033	Single Source Drug	None	1	Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive.	None	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=662	None
Rx0000414	Vifor Pharma Inc.	06/30/2022	53436025230	Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 25.2 grams	04/01/2022	23.56	965.92	10/08/2033	Single Source Drug	None	1	Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive.	None	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=663	None
Rx0000414	Vifor Pharma Inc.	06/30/2022	53436008430	Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 8.4 grams	04/01/2022	23.56	965.92	10/08/2033	Single Source Drug	None	1	Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive.	None	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=661	None
Rx0000381	Wockhardt USA LLC	06/30/2022	60432015016	Hydroxyzine HCL Syrup 10MG	04/29/2022	29.27	61.22	None	Non-innovator Multiple Source Drug	70000	None	Following market conditions	None	Following market conditions	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000223	Woodward Pharma Services LLC	03/31/2022	69784023120	Sodium Acetate Inj 2 mEq/ML, 100 ML, Glass Cont Qty 20	02/03/2022	173.37	300.00	None	Non-innovator Multiple Source Drug	20050	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000223	Woodward Pharma Services LLC	03/31/2022	69784023020	Sodium Acetate Inj 2 mEq/ML, 50 ML, Vial Qty 20	02/03/2022	126.54	219.00	None	Non-innovator Multiple Source Drug	9889	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	This increase is a result of an increase in the cost of producing the raw materials, components, manufacturing of the finished dose product, and an increase in the cost of transportation.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000380	Xeris Pharmaceuticals, INC.	03/31/2022	71090000101	Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100	02/01/2022	2471.36	27434.64	08/07/2022	Single Source Drug	None	1	None	1	None	1	12/12/2016	Taro Pharmaceuticals Industries	8500000	None	None	13650.00	13650.00	2015	13650.00	None	None
Rx0000380	Xeris Pharmaceuticals, INC.	09/30/2022	71090000101	Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100	08/01/2022	2716.03	30150.67	08/07/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000380	Xeris Pharmaceuticals, INC.	12/31/2022	72065000301	Levoketoconazole (Recorlev) 150 MG/1 Oral Tablet 50 tablets in 1 bottle	12/30/2022	1468.81	16305.31	03/02/2040	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000082	Zydus Pharmaceuticals (USA) Inc.	06/30/2022	68382018701	Dipyridamole 25 mg Tablets 100 ct	05/05/2022	36.09	55.94	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This is an AB rated generic drug that was not acquired in the last 5 years. This drug was discontinued in 2015 and obsoleted from the market in 2016 based on last lot expiration date. Zydus relaunched on May 5, 2022. There were no sales of this product in the last 5 years.
Rx0000082	Zydus Pharmaceuticals (USA) Inc.	06/30/2022	68382018801	Dipyridamole 50 mg Tablets 100 ct	05/05/2022	58.14	90.11	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This is an AB rated generic drug that was not acquired in the last 5 years. This drug was discontinued in 2015 and obsoleted from the market in 2016 based on last lot expiration date. Zydus relaunched on May 5, 2022. There were no sales of this product in the last 5 years.
Rx0000082	Zydus Pharmaceuticals (USA) Inc.	06/30/2022	68382018901	Dipyridamole 75 mg Tablets 100 ct	05/05/2022	77.79	120.57	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This is an AB rated generic drug that was not acquired in the last 5 years. This drug was discontinued in 2015 and obsoleted from the market in 2016 based on last lot expiration date. Zydus relaunched on May 5, 2022. There were no sales of this product in the last 5 years.
Rx0000163	Zyla Life Sciences	03/31/2022	69344010101	Indomethacin Oral Suspension 25 mg per 5mL - 237mL/Bottle	02/01/2022	194.10	2154.67	None	Single Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None	None	01/31/2019	Iroko Pharmaceuticals, Inc	87000000	None	What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	891.98	891.98	1985	232.17	None	Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013).
Rx0000163	Zyla Life Sciences	03/31/2022	42211010111	Indomethacin Oral Suspension 25 mg per 5mL (237mL/Bottle) Disc NDC	02/01/2022	194.10	2154.67	None	Single Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None	None	01/31/2019	Iroko Pharmaceuticals, Inc	87000000	None	What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	891.98	891.98	1985	232.17	None	Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013).
Rx0000163	Zyla Life Sciences	03/31/2022	69344011311	OXAYDO (Oxycodone HCL Tablet) 5 MG 100 CT BOTTLE	02/01/2022	87.81	974.74	03/16/2025	Single Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years.
Rx0000163	Zyla Life Sciences	03/31/2022	69344021311	OXAYDO (Oxycodone HCL Tablet) 7.5 MG 100 CT BOTTLE	02/01/2022	131.56	1460.52	03/16/2025	Single Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years.
Rx0000163	Zyla Life Sciences	03/31/2022	69344014443	Sprix 15.75mg/1 Spray, Metered (5 Bottles per Carton)	02/01/2022	144.97	2245.94	None	Innovator Multiple Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years.
Rx0000163	Zyla Life Sciences	03/31/2022	69344020429	Zorvolex 35 MG Capsule 90 EA	02/01/2022	70.72	785.07	04/23/2030	Single Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None	None	01/31/2019	Iroko Pharmaceuticals, Inc	87000000	None	What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	383.05	350.14	2013	225.00	None	Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013).
Rx0000163	Zyla Life Sciences	03/31/2022	42211020429	Zorvolex 35 MG Capsule 90 EA - Disc NDC	02/01/2022	70.72	785.07	04/23/2030	Single Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None	None	01/31/2019	Iroko Pharmaceuticals, Inc	87000000	None	What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	383.05	350.14	2013	225.00	None	Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013).